trial_id
stringlengths 11
11
| question
stringlengths 154
5.24k
| options
dict | answer
stringclasses 4
values | trials
listlengths 4
4
| id
int64 0
27.3k
| split
stringclasses 2
values |
|---|---|---|---|---|---|---|
NCT00041119
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Brief Summary: This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes. Giving additional cancer treatment after surgery may help to lower the risk that the cancer will come back (adjuvant therapy). Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether the standard adjuvant therapy of cyclophosphamide and doxorubicin hydrochloride is more effective than paclitaxel in treating women with breast cancer
|
{
"A": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: methotrexate, Drug: 5-fluorouracil | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: docetaxel | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): B | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): A",
"B": "Arm Label: Arm A Taxane-containing; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Arm B standard anthracyclin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel; Assigned to Arm(s): Arm A Taxane-containing, Arm B standard anthracyclin",
"C": "Arm Label: Arm A: FAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-fluorouracil, Drug: Doxorubicin, Drug: Cyclophosphamide | Arm Label: Arm B: TAC; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Doxorubicin, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: TAC | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Arm A: FAC | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A: FAC, Arm B: TAC | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A: FAC, Arm B: TAC",
"D": "Arm Label: Arm I (CA for 4 courses); Type: ACTIVE_COMPARATOR; Interventions: Drug: AC regimen, Drug: doxorubicin hydrochloride | Arm Label: Arm II (CA for 6 courses [closed to accrual 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride | Arm Label: Arm III (paclitaxel for 4 courses); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Arm Label: Arm IV (paclitaxel for 6 courses [closed 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Intervention Type: DRUG; Name: AC regimen; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]), Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007]) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007])"
}
|
D
|
[
"NCT00331097",
"NCT01222052",
"NCT00121992",
"NCT00041119"
] | 500 |
train
|
NCT00041938
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
Brief Summary: The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function.
We are now transitioning into the sub-analysis part of the WARCEF patient data.
The study has recently completed data analysis for its Primary Aim. All randomized patients have completed their follow up. All study related procedure as per the protocol has been completed. We are now in the extension phase of the study to obtain more patient data to address further aims of the study. No new procedures are performed and data already in place at the sites will be collected (EKG and echocardiograms).
The aims for this study extension are:
* To assess progression of cardiac dysfunction over time among heart failure patients
* To correlate prognosis with cardiac dysfunction
|
{
"A": "Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)",
"B": "Arm Label: Rivaroxaban 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Other: Standard of care for heart failure and coronary artery disease | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of care for heart failure and coronary artery disease | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban 2.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Standard of care for heart failure and coronary artery disease; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 | Intervention Type: DRUG; Name: Warfarin titrated to an INR of 2.5-3.0; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Clopidogrel 75; Assigned to Arm(s): 3",
"D": "Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): aspirin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): warfarin"
}
|
D
|
[
"NCT00571649",
"NCT01877915",
"NCT00007683",
"NCT00041938"
] | 501 |
train
|
NCT00042198
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Depression After Coronary Bypass Surgery
Brief Summary: This randomized controlled trial will test the efficacy of (1) cognitive behavior therapy and (2) supportive stress management as treatments for depression in people who have recently undergone coronary artery bypass graft surgery.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Stress Management | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive Stress Management; Assigned to Arm(s): 2",
"B": "Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care",
"C": "Arm Label: Cardiac rehabilitation+cognitive therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Group based cognitive therapy | Arm Label: Cardiac rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control group without psychological distress; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group based cognitive therapy; Assigned to Arm(s): Cardiac rehabilitation+cognitive therapy",
"D": "Arm Label: real-time, face-to-face, video-conferenced CBT (vcCBT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Online cognitive behavioral therapy | Arm Label: self-administered internet-based CBT (iCBT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Online cognitive behavioral therapy | Intervention Type: BEHAVIORAL; Name: Online cognitive behavioral therapy; Assigned to Arm(s): real-time, face-to-face, video-conferenced CBT (vcCBT), self-administered internet-based CBT (iCBT)"
}
|
A
|
[
"NCT00042198",
"NCT00091962",
"NCT04254315",
"NCT04986969"
] | 502 |
train
|
NCT00042198
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Depression After Coronary Bypass Surgery
Brief Summary: This randomized controlled trial will test the efficacy of (1) cognitive behavior therapy and (2) supportive stress management as treatments for depression in people who have recently undergone coronary artery bypass graft surgery.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2",
"B": "Arm Label: Collaborative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: Collaborative Care Treatment; Assigned to Arm(s): Collaborative Care | Intervention Type: BEHAVIORAL; Name: Usual Care Treatment; Assigned to Arm(s): Usual Care",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Stress Management | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive Stress Management; Assigned to Arm(s): 2",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy, Other: Usual cardiological care | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information session, Other: Usual cardiological care | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Information session; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Usual cardiological care; Assigned to Arm(s): 1, 2"
}
|
C
|
[
"NCT00508508",
"NCT00847132",
"NCT00042198",
"NCT00705965"
] | 503 |
train
|
NCT00042198
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Depression After Coronary Bypass Surgery
Brief Summary: This randomized controlled trial will test the efficacy of (1) cognitive behavior therapy and (2) supportive stress management as treatments for depression in people who have recently undergone coronary artery bypass graft surgery.
|
{
"A": "Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral interventional program | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral interventional program | Intervention Type: BEHAVIORAL; Name: Behavioral interventional program; Assigned to Arm(s): Behavioral intervention, Standard treatment",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Stress Management | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive Stress Management; Assigned to Arm(s): 2",
"C": "Arm Label: WBT-WEB; Type: EXPERIMENTAL; Interventions: Behavioral: Well-Being Therapy based on Web Mobile Technology | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy | Arm Label: CM; Type: NO_INTERVENTION; Interventions: Other: Standardized Care Management | Intervention Type: BEHAVIORAL; Name: Well-Being Therapy based on Web Mobile Technology; Assigned to Arm(s): WBT-WEB | Intervention Type: BEHAVIORAL; Name: Cognitive Behavior Therapy; Assigned to Arm(s): CBT | Intervention Type: OTHER; Name: Standardized Care Management; Assigned to Arm(s): CM",
"D": "Arm Label: ACT-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACT-based intervention, Behavioral: usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: ACT-based intervention; Assigned to Arm(s): ACT-based intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): ACT-based intervention, Usual care"
}
|
B
|
[
"NCT00888485",
"NCT00042198",
"NCT01543815",
"NCT01909102"
] | 504 |
train
|
NCT00042211
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Depression in Macular Degeneration
Brief Summary: This study will evaluate the effectiveness of a Problem Solving Treatment in preventing depression in elderly patients with age-related macular degeneration (AMD).
|
{
"A": "Arm Label: BA-LVR; Type: EXPERIMENTAL; Interventions: Behavioral: BA-LVR | Arm Label: ST-LVR; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: ST-LVR | Intervention Type: BEHAVIORAL; Name: BA-LVR; Assigned to Arm(s): BA-LVR | Intervention Type: BEHAVIORAL; Name: ST-LVR; Assigned to Arm(s): ST-LVR",
"B": "Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Problem Solving Treatment; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2",
"D": "Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet"
}
|
C
|
[
"NCT00769015",
"NCT00536172",
"NCT00042211",
"NCT00097669"
] | 505 |
train
|
NCT00042211
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Depression in Macular Degeneration
Brief Summary: This study will evaluate the effectiveness of a Problem Solving Treatment in preventing depression in elderly patients with age-related macular degeneration (AMD).
|
{
"A": "Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Problem Solving Treatment; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2",
"C": "Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Low Vision Intervention - Outpatient Training Program | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Vision Intervention - Outpatient Training Program; Assigned to Arm(s): Arm 1",
"D": "Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg"
}
|
B
|
[
"NCT00687804",
"NCT00042211",
"NCT00223756",
"NCT00473382"
] | 506 |
train
|
NCT00043082
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
|
{
"A": "Arm Label: CAELYX; Type: EXPERIMENTAL; Interventions: Drug: CAELYX | Arm Label: Topotecan hydrochloride (HCl); Type: ACTIVE_COMPARATOR; Interventions: Drug: Topotecan HCl | Intervention Type: DRUG; Name: CAELYX; Assigned to Arm(s): CAELYX | Intervention Type: DRUG; Name: Topotecan HCl; Assigned to Arm(s): Topotecan hydrochloride (HCl)",
"B": "Arm Label: Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Triple-negative Breast Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: BRCA- positive Ovarian Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: ABT-888; Assigned to Arm(s): BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): BRCA- positive Ovarian Cancer: Cyclophosphamide Alone, BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Non-Hodgkin's: Cyclophosphamide Alone, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: Cyclophosphamide Alone",
"C": "Arm Label: Arm I (adjuvant chemotherapy suboptimally debulked); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (neoadjuvant chemotherapy); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy)",
"D": "Arm Label: carboplatin and doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: pegylated liposomal doxorubicin hydrochloride | Arm Label: carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): carboplatin, carboplatin and doxorubicin | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin hydrochloride; Assigned to Arm(s): carboplatin and doxorubicin"
}
|
D
|
[
"NCT01840943",
"NCT01306032",
"NCT01167712",
"NCT00043082"
] | 507 |
train
|
NCT00043537
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Childhood Social Phobia
Brief Summary: This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents.
|
{
"A": "Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: family based cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: family based cognitive behavior therapy; Assigned to Arm(s): 2",
"B": "Arm Label: Social Effectiveness Therapy for Children; Type: EXPERIMENTAL; Interventions: Behavioral: Social Effectiveness Therapy for Children (SET-C) | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Pill placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pill Placebo | Intervention Type: BEHAVIORAL; Name: Social Effectiveness Therapy for Children (SET-C); Assigned to Arm(s): Social Effectiveness Therapy for Children | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Pill Placebo; Assigned to Arm(s): Pill placebo",
"C": "Arm Label: Sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT) | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: SRT + CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT), Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline (SRT); Assigned to Arm(s): SRT + CBT, Sertraline | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT, SRT + CBT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive Behavioral Therapy"
}
|
B
|
[
"NCT00255112",
"NCT00043537",
"NCT00052078",
"NCT00280670"
] | 508 |
train
|
NCT00043537
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Childhood Social Phobia
Brief Summary: This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents.
|
{
"A": "Arm Label: 1. Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: 2. Client Centered Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Client Centered Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): 1. Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Client Centered Therapy; Assigned to Arm(s): 2. Client Centered Therapy",
"B": "Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT | Arm Label: WL; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): CBT",
"C": "Arm Label: Social Effectiveness Therapy for Children; Type: EXPERIMENTAL; Interventions: Behavioral: Social Effectiveness Therapy for Children (SET-C) | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Pill placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pill Placebo | Intervention Type: BEHAVIORAL; Name: Social Effectiveness Therapy for Children (SET-C); Assigned to Arm(s): Social Effectiveness Therapy for Children | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Pill Placebo; Assigned to Arm(s): Pill placebo",
"D": "Arm Label: Cognitive-Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-Behavioral Therapy | Arm Label: Wait-list; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): Cognitive-Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Wait-list; Assigned to Arm(s): Wait-list"
}
|
C
|
[
"NCT00774150",
"NCT02908321",
"NCT00043537",
"NCT01177969"
] | 509 |
train
|
NCT00044434
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bupropion as a Smoking Cessation Aid in Alcoholics
Brief Summary: The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"B": "Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A",
"C": "Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only",
"D": "Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00129311",
"NCT00044434",
"NCT01553084",
"NCT00141206"
] | 510 |
train
|
NCT00044434
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bupropion as a Smoking Cessation Aid in Alcoholics
Brief Summary: The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.
|
{
"A": "Arm Label: Tailored intervention; Type: EXPERIMENTAL; Interventions: Drug: Nicotine replacement therapy - Transdermal nicotine patch, Drug: Nicotine replacement therapy - Nicotine gum, Drug: Nicotine replacement therapy - Nicotine lozenge, Drug: Bupropion, Drug: Varenicline, Drug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum, Drug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge, Drug: Combination pharmacotherapy - Transdermal nicotine patch + bupropion, Behavioral: Tailored behavioral intervention, Behavioral: Alcohol use risk reduction, Behavioral: Behavioral activation for depressive symptoms, Behavioral: Behavioral management of postcessation weight gain | Arm Label: Enhanced standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine replacement therapy - Transdermal nicotine patch, Drug: Nicotine replacement therapy - Nicotine gum, Drug: Nicotine replacement therapy - Nicotine lozenge, Drug: Bupropion, Drug: Varenicline, Drug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum, Drug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge, Drug: Combination pharmacotherapy - Transdermal nicotine patch + bupropion, Behavioral: Tobacco quitline referral | Intervention Type: DRUG; Name: Nicotine replacement therapy - Transdermal nicotine patch; Assigned to Arm(s): Enhanced standard of care, Tailored intervention | Intervention Type: DRUG; Name: Nicotine replacement therapy - Nicotine gum; Assigned to Arm(s): Enhanced standard of care, Tailored intervention | Intervention Type: DRUG; Name: Nicotine replacement therapy - Nicotine lozenge; Assigned to Arm(s): Enhanced standard of care, Tailored intervention | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Enhanced standard of care, Tailored intervention | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Enhanced standard of care, Tailored intervention | Intervention Type: DRUG; Name: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum; Assigned to Arm(s): Enhanced standard of care, Tailored intervention | Intervention Type: DRUG; Name: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge; Assigned to Arm(s): Enhanced standard of care, Tailored intervention | Intervention Type: DRUG; Name: Combination pharmacotherapy - Transdermal nicotine patch + bupropion; Assigned to Arm(s): Enhanced standard of care, Tailored intervention | Intervention Type: BEHAVIORAL; Name: Tobacco quitline referral; Assigned to Arm(s): Enhanced standard of care | Intervention Type: BEHAVIORAL; Name: Tailored behavioral intervention; Assigned to Arm(s): Tailored intervention | Intervention Type: BEHAVIORAL; Name: Alcohol use risk reduction; Assigned to Arm(s): Tailored intervention | Intervention Type: BEHAVIORAL; Name: Behavioral activation for depressive symptoms; Assigned to Arm(s): Tailored intervention | Intervention Type: BEHAVIORAL; Name: Behavioral management of postcessation weight gain; Assigned to Arm(s): Tailored intervention",
"B": "Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P",
"C": "Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2"
}
|
C
|
[
"NCT01892813",
"NCT00689611",
"NCT00044434",
"NCT00142831"
] | 511 |
train
|
NCT00044434
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bupropion as a Smoking Cessation Aid in Alcoholics
Brief Summary: The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.
|
{
"A": "Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose",
"B": "Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A",
"C": "Arm Label: Group I (varenicline and placebo); Type: EXPERIMENTAL; Interventions: Other: Placebo, Other: Tobacco Cessation Counseling, Drug: Varenicline | Arm Label: Group II (placebo, nicotine patch and lozenge); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nicotine Lozenge, Drug: Nicotine Patch, Other: Placebo, Other: Tobacco Cessation Counseling | Intervention Type: DRUG; Name: Nicotine Lozenge; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Group I (varenicline and placebo)",
"D": "Arm Label: Combination zonisamide and bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Zonisamide, Other: E-cigarette | Arm Label: Bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Arm Label: Placebo with e-cigarette; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Placebo bupropion; Assigned to Arm(s): Placebo with e-cigarette | Intervention Type: DRUG; Name: Placebo zonisamide; Assigned to Arm(s): Bupropion with e-cigarette, Placebo with e-cigarette | Intervention Type: OTHER; Name: E-cigarette; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette, Placebo with e-cigarette"
}
|
B
|
[
"NCT01206010",
"NCT00044434",
"NCT02271919",
"NCT05205811"
] | 512 |
train
|
NCT00044434
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bupropion as a Smoking Cessation Aid in Alcoholics
Brief Summary: The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.
|
{
"A": "Intervention Type: DRUG; Name: sustained-release bupropion (Zyban(R)); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychodynamic Model Training (R) = PDM(R); Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A",
"C": "Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban",
"D": "Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo"
}
|
B
|
[
"NCT00484692",
"NCT00044434",
"NCT01806779",
"NCT00813917"
] | 513 |
train
|
NCT00044434
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bupropion as a Smoking Cessation Aid in Alcoholics
Brief Summary: The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.
|
{
"A": "Arm Label: Gain Framed Absitnence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Arm Label: Loss Framed Abstinence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program | Intervention Type: BEHAVIORAL; Name: Smoking Abstinence Program; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program",
"B": "Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo",
"C": "Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00104598",
"NCT00835900",
"NCT00595868",
"NCT00044434"
] | 514 |
train
|
NCT00044655
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Switching Antipsychotic Medications
Brief Summary: This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
|
{
"A": "Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2",
"B": "Arm Label: Risperidone, Intensive; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: risperidone, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: olanzapine, intensive; Type: EXPERIMENTAL; Interventions: Drug: olanzapine | Arm Label: olanzapine, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: aripiprazole, intensive; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: aripiprazole, basiv; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Risperidone, Intensive, risperidone, basic | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): olanzapine, basic, olanzapine, intensive | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): aripiprazole, basiv, aripiprazole, intensive",
"C": "Arm Label: Aripiprazole depot; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot | Arm Label: Placebo depot; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo depot | Intervention Type: DRUG; Name: Aripiprazole depot; Assigned to Arm(s): Aripiprazole depot | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Placebo depot",
"D": "Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol"
}
|
D
|
[
"NCT00300846",
"NCT01057849",
"NCT00705783",
"NCT00044655"
] | 515 |
train
|
NCT00044655
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Switching Antipsychotic Medications
Brief Summary: This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
|
{
"A": "Arm Label: RISPERDAL CONSTA; Type: ACTIVE_COMPARATOR; Interventions: Drug: RISPERDAL CONSTA | Arm Label: R092670; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone palmitate | Intervention Type: DRUG; Name: RISPERDAL CONSTA; Assigned to Arm(s): RISPERDAL CONSTA | Intervention Type: DRUG; Name: Paliperidone palmitate; Assigned to Arm(s): R092670",
"B": "Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol",
"C": "Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abilify | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidal Consta | Intervention Type: DRUG; Name: Abilify; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidal Consta; Assigned to Arm(s): 001",
"D": "Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00589914",
"NCT00044655",
"NCT00299702",
"NCT00210717"
] | 516 |
train
|
NCT00044655
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Switching Antipsychotic Medications
Brief Summary: This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
|
{
"A": "Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review",
"B": "Arm Label: Pharmacist Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pharmacist Intervention; Assigned to Arm(s): Pharmacist Intervention",
"C": "Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol",
"D": "Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: EHR Based Strategy to promote Safe and Appropriate Drug Use | Arm Label: Standard Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EHR Based Strategy to promote Safe and Appropriate Drug Use; Assigned to Arm(s): Intervention Arm"
}
|
C
|
[
"NCT01876095",
"NCT02275572",
"NCT00044655",
"NCT01669473"
] | 517 |
train
|
NCT00044655
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Switching Antipsychotic Medications
Brief Summary: This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
|
{
"A": "Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride",
"B": "Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Risperidone, long-acting injectable; Assigned to Arm(s): N/A",
"D": "Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol"
}
|
D
|
[
"NCT01615185",
"NCT00272584",
"NCT00297388",
"NCT00044655"
] | 518 |
train
|
NCT00045032
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy
Brief Summary: The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable. Efficacy and safety will be assessed for 10 years from randomization for each participant. All participants will continue to be followed for survival until 10 years after enrollment of the last participant.
|
{
"A": "Intervention Type: BIOLOGICAL; Name: trastuzumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A",
"B": "Arm Label: Observation Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Herceptin 1-Year Arm; Type: EXPERIMENTAL; Interventions: Drug: Herceptin | Arm Label: Herceptin 2-Year Arm; Type: EXPERIMENTAL; Interventions: Drug: Herceptin | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): Herceptin 1-Year Arm | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): Herceptin 2-Year Arm",
"C": "Arm Label: Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin, Drug: Cyclophosphamide, Drug: Docetaxel | Arm Label: AC followed by Docetaxel + Herceptin (AC→TH); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin, Drug: Cyclophosphamide, Drug: Docetaxel, Drug: Herceptin | Arm Label: Docetaxel + Carboplatin + Herceptin (TCH); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Herceptin, Drug: Carboplatin | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Docetaxel + Carboplatin + Herceptin (TCH), Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T) | Intervention Type: DRUG; Name: Herceptin; Assigned to Arm(s): AC followed by Docetaxel + Herceptin (AC→TH), Docetaxel + Carboplatin + Herceptin (TCH) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Docetaxel + Carboplatin + Herceptin (TCH)",
"D": "Intervention Type: BIOLOGICAL; Name: trastuzumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aromatase inhibition therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: releasing hormone agonist therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00288002",
"NCT00045032",
"NCT00021255",
"NCT00629278"
] | 519 |
train
|
NCT00046020
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially With Venlafaxine ER
Brief Summary: The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
|
{
"A": "Arm Label: Mindfulness Based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: Combination; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy, Drug: Optimal Medical Care | Arm Label: Optimal Medical Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal Medical Care | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): Combination, Mindfulness Based Cognitive Therapy | Intervention Type: DRUG; Name: Optimal Medical Care; Assigned to Arm(s): Combination, Optimal Medical Care",
"B": "Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A",
"C": "Arm Label: Mindfulness-based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based Cognitive Therapy, Biological: Standard psychiatric care | Arm Label: CBASP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: The Cognitive Behavioral Analysis System of Psychotherapy, Biological: Standard psychiatric care | Arm Label: Treatment-as-usual; Type: ACTIVE_COMPARATOR; Interventions: Biological: Standard psychiatric care | Intervention Type: BEHAVIORAL; Name: Mindfulness-based Cognitive Therapy; Assigned to Arm(s): Mindfulness-based Cognitive Therapy | Intervention Type: BEHAVIORAL; Name: The Cognitive Behavioral Analysis System of Psychotherapy; Assigned to Arm(s): CBASP | Intervention Type: BIOLOGICAL; Name: Standard psychiatric care; Assigned to Arm(s): CBASP, Mindfulness-based Cognitive Therapy, Treatment-as-usual",
"D": "Arm Label: Behavioral Activation for Return to Work; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for return to work | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for return to work; Assigned to Arm(s): Behavioral Activation for Return to Work"
}
|
B
|
[
"NCT00928980",
"NCT00046020",
"NCT01065311",
"NCT01783080"
] | 520 |
train
|
NCT00046020
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially With Venlafaxine ER
Brief Summary: The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
|
{
"A": "Arm Label: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg | Arm Label: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release Formulation 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release Formulation 25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Desvenlafaxine succinate sustained release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine succinate sustained release 50 mg, Drug: Desvenlafaxine succinate sustained release 25 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desvenlafaxine succinate sustained release 50 mg; Assigned to Arm(s): Desvenlafaxine succinate sustained release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine succinate sustained release 25 mg; Assigned to Arm(s): Desvenlafaxine succinate sustained release 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A",
"D": "Arm Label: Supported Protocolized Discontinuation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD) | Arm Label: SPD + Mindfulness (MBCT); Type: EXPERIMENTAL; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD), Behavioral: Mindfulness Based Cognitive Therapy (MBCT) | Intervention Type: BEHAVIORAL; Name: Supported Protocolized Discontinuation (SPD); Assigned to Arm(s): SPD + Mindfulness (MBCT), Supported Protocolized Discontinuation | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy (MBCT); Assigned to Arm(s): SPD + Mindfulness (MBCT)"
}
|
C
|
[
"NCT01056289",
"NCT00887224",
"NCT00046020",
"NCT03361514"
] | 521 |
train
|
NCT00046254
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.
|
{
"A": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A",
"C": "Arm Label: Zoledronic Acid 2x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Zoledronic Acid 1x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): Zoledronic Acid 1x5 mg, Zoledronic Acid 2x5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Zoledronic Acid 1x5 mg",
"D": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00100620",
"NCT00046254",
"NCT00132808",
"NCT00097825"
] | 522 |
train
|
NCT00046254
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.
|
{
"A": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A",
"C": "Arm Label: Zoledronic Acid 2x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Zoledronic Acid 1x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): Zoledronic Acid 1x5 mg, Zoledronic Acid 2x5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Zoledronic Acid 1x5 mg",
"D": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00049829",
"NCT00100620",
"NCT00132808",
"NCT00046254"
] | 523 |
train
|
NCT00047008
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas
Brief Summary: RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways and combining it with chemotherapy before surgery may kill more tumor cells. It is not yet known which radiation therapy regimen combined with chemotherapy with or without surgery is more effective for head and neck cancer.
PURPOSE: Randomized phase III trial to compare two different radiation therapy regimens combined with cisplatin with or without surgery in treating patients who have stage III or stage IV head and neck cancer.
|
{
"A": "Arm Label: Surgery and radiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TPF induction chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: TPF induction chemotherapy | Intervention Type: DRUG; Name: TPF induction chemotherapy; Assigned to Arm(s): TPF induction chemotherapy",
"B": "Arm Label: Radiotherapy plus or minus Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Arm Label: Transoral Robotic Surgery + Neck Dissection; Type: EXPERIMENTAL; Interventions: Procedure: Transoral Robotic Surgery + Neck Dissection | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy plus or minus Chemotherapy | Intervention Type: PROCEDURE; Name: Transoral Robotic Surgery + Neck Dissection; Assigned to Arm(s): Transoral Robotic Surgery + Neck Dissection",
"C": "Arm Label: Wait and Watch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Therapeutic Neck Dissection | Arm Label: Elective Neck dissection; Type: EXPERIMENTAL; Interventions: Procedure: Elective neck dissection in early oral cancer | Intervention Type: PROCEDURE; Name: Elective neck dissection in early oral cancer; Assigned to Arm(s): Elective Neck dissection | Intervention Type: PROCEDURE; Name: Therapeutic Neck Dissection; Assigned to Arm(s): Wait and Watch",
"D": "Arm Label: Standard fractionation RT + cisplatin; Type: OTHER; Interventions: Drug: cisplatin, Radiation: Standard fractionation RT, Procedure: Conventional surgery for select patients | Arm Label: Accelerated fractionation RT + cisplatin; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Radiation: Accelerated fractionation radiation therapy, Procedure: Conventional surgery for select patients | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Standard fractionation RT; Assigned to Arm(s): Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Accelerated fractionation radiation therapy; Assigned to Arm(s): Accelerated fractionation RT + cisplatin | Intervention Type: PROCEDURE; Name: Conventional surgery for select patients; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin"
}
|
D
|
[
"NCT01542931",
"NCT01590355",
"NCT00193765",
"NCT00047008"
] | 524 |
train
|
NCT00047008
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas
Brief Summary: RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways and combining it with chemotherapy before surgery may kill more tumor cells. It is not yet known which radiation therapy regimen combined with chemotherapy with or without surgery is more effective for head and neck cancer.
PURPOSE: Randomized phase III trial to compare two different radiation therapy regimens combined with cisplatin with or without surgery in treating patients who have stage III or stage IV head and neck cancer.
|
{
"A": "Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II",
"B": "Arm Label: Standard fractionation RT + cisplatin; Type: OTHER; Interventions: Drug: cisplatin, Radiation: Standard fractionation RT, Procedure: Conventional surgery for select patients | Arm Label: Accelerated fractionation RT + cisplatin; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Radiation: Accelerated fractionation radiation therapy, Procedure: Conventional surgery for select patients | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Standard fractionation RT; Assigned to Arm(s): Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Accelerated fractionation radiation therapy; Assigned to Arm(s): Accelerated fractionation RT + cisplatin | Intervention Type: PROCEDURE; Name: Conventional surgery for select patients; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin",
"C": "Intervention Type: DRUG; Name: XRP6976 (Docetaxel/Taxotere); Assigned to Arm(s): N/A",
"D": "Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: docetaxel, Drug: fluorouracil | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I"
}
|
B
|
[
"NCT00004227",
"NCT00047008",
"NCT00273546",
"NCT00095875"
] | 525 |
train
|
NCT00047424
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stop Atherosclerosis in Native Diabetics Study
Brief Summary: Compared to standard treatment goals achieving lower targets for LDL cholesterol (bad cholesterol) and blood pressure in people with diabetes will slow the progression of atherosclerosis as measured by carotid artery thickness, and reduce clinical cardiovascular events such as heart attacks and strokes. This study is a randomized 3-year trial. The primary endpoint will be a combination of various measures of the carotid artery, (which is an easy, non-invasive way to detect cardiovascular disease) and events such as heart attacks and strokes. The study will also look at secondary endpoints such as how well the heart pumps, fat,protein and inflammatory markers in the blood,and kidney function. The study enrolled 549 American Indian men and women with diabetes, \> 40 years of age and is being conducted in four field centers involving Indian Health Service/Tribal primary care facilities in Phoenix/Sacaton, Arizona; Chinle, Arizona; Rapid City/Pine Ridge, South Dakota; and Lawton, Oklahoma, with input from American Indian physicians and community members.
|
{
"A": "Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group",
"B": "Arm Label: SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: OTHER; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Intervention Type: DRUG; Name: all approved antihypertensive drugs; all approved statins; Assigned to Arm(s): SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 125 mmHg and LDL-C < 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l",
"C": "Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard",
"D": "Arm Label: The intensive care group; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine 5mg, Drug: Losartan, Drug: Losartan and Amlodipine, Drug: Amlodipine/Losartan/Chlorthalidone | Arm Label: The usual care group; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine 5mg, Drug: Losartan, Drug: Losartan and Amlodipine, Drug: Amlodipine/Losartan/Chlorthalidone, Drug: current treatment | Intervention Type: DRUG; Name: Amlodipine 5mg; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: Losartan and Amlodipine; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: Amlodipine/Losartan/Chlorthalidone; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: current treatment; Assigned to Arm(s): The usual care group"
}
|
A
|
[
"NCT00047424",
"NCT01563731",
"NCT01650402",
"NCT03666351"
] | 526 |
train
|
NCT00047424
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stop Atherosclerosis in Native Diabetics Study
Brief Summary: Compared to standard treatment goals achieving lower targets for LDL cholesterol (bad cholesterol) and blood pressure in people with diabetes will slow the progression of atherosclerosis as measured by carotid artery thickness, and reduce clinical cardiovascular events such as heart attacks and strokes. This study is a randomized 3-year trial. The primary endpoint will be a combination of various measures of the carotid artery, (which is an easy, non-invasive way to detect cardiovascular disease) and events such as heart attacks and strokes. The study will also look at secondary endpoints such as how well the heart pumps, fat,protein and inflammatory markers in the blood,and kidney function. The study enrolled 549 American Indian men and women with diabetes, \> 40 years of age and is being conducted in four field centers involving Indian Health Service/Tribal primary care facilities in Phoenix/Sacaton, Arizona; Chinle, Arizona; Rapid City/Pine Ridge, South Dakota; and Lawton, Oklahoma, with input from American Indian physicians and community members.
|
{
"A": "Arm Label: Extended release niacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: extended release niacin, Drug: ezetimibe | Arm Label: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: ezetimibe | Intervention Type: DRUG; Name: extended release niacin; Assigned to Arm(s): Extended release niacin | Intervention Type: DRUG; Name: ezetimibe; Assigned to Arm(s): Extended release niacin, Ezetimibe",
"B": "Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe, Drug: Niaspan, Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Procedure: Percutaneous transluminal angioplasty (PTA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Drug: Placebo Niaspan, Drug: Placebo Ezetimibe, Procedure: Percutaneous transluminal angioplasty (PTA) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Niaspan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo Niaspan; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Ezetimibe; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Percutaneous transluminal angioplasty (PTA); Assigned to Arm(s): 1, 2",
"D": "Intervention Type: DRUG; Name: MK0653, ezetimibe; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: statins; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00397657",
"NCT00047424",
"NCT00687076",
"NCT00092586"
] | 527 |
train
|
NCT00047424
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stop Atherosclerosis in Native Diabetics Study
Brief Summary: Compared to standard treatment goals achieving lower targets for LDL cholesterol (bad cholesterol) and blood pressure in people with diabetes will slow the progression of atherosclerosis as measured by carotid artery thickness, and reduce clinical cardiovascular events such as heart attacks and strokes. This study is a randomized 3-year trial. The primary endpoint will be a combination of various measures of the carotid artery, (which is an easy, non-invasive way to detect cardiovascular disease) and events such as heart attacks and strokes. The study will also look at secondary endpoints such as how well the heart pumps, fat,protein and inflammatory markers in the blood,and kidney function. The study enrolled 549 American Indian men and women with diabetes, \> 40 years of age and is being conducted in four field centers involving Indian Health Service/Tribal primary care facilities in Phoenix/Sacaton, Arizona; Chinle, Arizona; Rapid City/Pine Ridge, South Dakota; and Lawton, Oklahoma, with input from American Indian physicians and community members.
|
{
"A": "Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A",
"C": "Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2"
}
|
C
|
[
"NCT00231738",
"NCT00327418",
"NCT00047424",
"NCT00668343"
] | 528 |
train
|
NCT00047424
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stop Atherosclerosis in Native Diabetics Study
Brief Summary: Compared to standard treatment goals achieving lower targets for LDL cholesterol (bad cholesterol) and blood pressure in people with diabetes will slow the progression of atherosclerosis as measured by carotid artery thickness, and reduce clinical cardiovascular events such as heart attacks and strokes. This study is a randomized 3-year trial. The primary endpoint will be a combination of various measures of the carotid artery, (which is an easy, non-invasive way to detect cardiovascular disease) and events such as heart attacks and strokes. The study will also look at secondary endpoints such as how well the heart pumps, fat,protein and inflammatory markers in the blood,and kidney function. The study enrolled 549 American Indian men and women with diabetes, \> 40 years of age and is being conducted in four field centers involving Indian Health Service/Tribal primary care facilities in Phoenix/Sacaton, Arizona; Chinle, Arizona; Rapid City/Pine Ridge, South Dakota; and Lawton, Oklahoma, with input from American Indian physicians and community members.
|
{
"A": "Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group",
"B": "Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A",
"C": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"D": "Intervention Type: DRUG; Name: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atenolol/HCTZ/Trandolapril; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00047424",
"NCT00153101",
"NCT00000620",
"NCT00133692"
] | 529 |
train
|
NCT00047437
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
Brief Summary: The purpose of this study is to determine the long-term safety and effectiveness of exercise training for individuals with congestive heart failure (CHF).
|
{
"A": "Arm Label: Soccer Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Soccer training | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soccer training; Assigned to Arm(s): Soccer Training",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): 1, 2, 3",
"C": "Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Resistance Exercise Training; Assigned to Arm(s): N/A",
"D": "Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2"
}
|
D
|
[
"NCT01711892",
"NCT00249015",
"NCT00115713",
"NCT00047437"
] | 530 |
train
|
NCT00047437
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
Brief Summary: The purpose of this study is to determine the long-term safety and effectiveness of exercise training for individuals with congestive heart failure (CHF).
|
{
"A": "Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control",
"B": "Intervention Type: BEHAVIORAL; Name: Aerobic endurance exercise training (ergometer); Assigned to Arm(s): N/A",
"C": "Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: 12-week Tai Chi Program | Arm Label: Heart Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 12-week Education Program | Intervention Type: BEHAVIORAL; Name: 12-week Tai Chi Program; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: 12-week Education Program; Assigned to Arm(s): Heart Health Education",
"D": "Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2"
}
|
D
|
[
"NCT01113840",
"NCT00176384",
"NCT00110227",
"NCT00047437"
] | 531 |
train
|
NCT00047437
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
Brief Summary: The purpose of this study is to determine the long-term safety and effectiveness of exercise training for individuals with congestive heart failure (CHF).
|
{
"A": "Arm Label: SSRI+ LD; Type: EXPERIMENTAL; Interventions: Behavioral: SSRI + LD | Arm Label: SSRI+ PHD; Type: EXPERIMENTAL; Interventions: Behavioral: SSRI + PHD | Intervention Type: BEHAVIORAL; Name: SSRI + LD; Assigned to Arm(s): SSRI+ LD | Intervention Type: BEHAVIORAL; Name: SSRI + PHD; Assigned to Arm(s): SSRI+ PHD",
"B": "Intervention Type: BEHAVIORAL; Name: Supervised Exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Home-Based Exercise; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline (Zoloft); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo Pill; Assigned to Arm(s): N/A",
"C": "Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Aerobic Exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Pill. | Intervention Type: BEHAVIORAL; Name: Supervised Aerobic Exercise; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Pill.; Assigned to Arm(s): 3"
}
|
C
|
[
"NCT00076258",
"NCT00331305",
"NCT00047437",
"NCT00302068"
] | 532 |
train
|
NCT00047437
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
Brief Summary: The purpose of this study is to determine the long-term safety and effectiveness of exercise training for individuals with congestive heart failure (CHF).
|
{
"A": "Arm Label: Exercise Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Dietary Intervention; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Dietary Intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Other: Attention Control | Arm Label: Diet and Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise, Behavioral: Diet and exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Diet and Exercise, Exercise Training | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Intervention; Assigned to Arm(s): Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Diet and exercise; Assigned to Arm(s): Diet and Exercise | Intervention Type: OTHER; Name: Attention Control; Assigned to Arm(s): Attention control",
"B": "Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2",
"C": "Arm Label: Control group (Group A); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Intervention group (Group B); Type: OTHER; Interventions: Other: Home-based telehealth program, Other: Home-based rehabilitation, Other: Usual care | Intervention Type: OTHER; Name: Home-based telehealth program; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Home-based rehabilitation; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control group (Group A), Intervention group (Group B)",
"D": "Arm Label: High Intensity Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: High Intensity Exercise | Arm Label: Moderate Continuous Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Moderate Continuous Exercise | Arm Label: Usual Care; Type: SHAM_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: High Intensity Exercise; Assigned to Arm(s): High Intensity Exercise | Intervention Type: BEHAVIORAL; Name: Moderate Continuous Exercise; Assigned to Arm(s): Moderate Continuous Exercise | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care"
}
|
B
|
[
"NCT00959660",
"NCT00047437",
"NCT02269618",
"NCT02078947"
] | 533 |
train
|
NCT00047437
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
Brief Summary: The purpose of this study is to determine the long-term safety and effectiveness of exercise training for individuals with congestive heart failure (CHF).
|
{
"A": "Arm Label: Cognitive Behavioral Stress Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Stress Management (CBSM) | Arm Label: Patient Education; Type: ACTIVE_COMPARATOR; Interventions: Other: Patient Education | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Stress Management (CBSM); Assigned to Arm(s): Cognitive Behavioral Stress Management | Intervention Type: OTHER; Name: Patient Education; Assigned to Arm(s): Patient Education",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: rehabilitation; Assigned to Arm(s): 1",
"C": "Arm Label: Cognitive Behavior Therapy - males; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Cognitive Behavior Therapy - females; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Usual Cardiac Care - Males; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Arm Label: Usual Cardiac Care - females; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Intervention Type: BEHAVIORAL; Name: Cognitive Behaviour Therapy (CBT); Assigned to Arm(s): Cognitive Behavior Therapy - females, Cognitive Behavior Therapy - males | Intervention Type: OTHER; Name: Usual Cardiac Care (UCC); Assigned to Arm(s): Usual Cardiac Care - Males, Usual Cardiac Care - females",
"D": "Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2"
}
|
D
|
[
"NCT00624520",
"NCT00569478",
"NCT00152763",
"NCT00047437"
] | 534 |
train
|
NCT00047437
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
Brief Summary: The purpose of this study is to determine the long-term safety and effectiveness of exercise training for individuals with congestive heart failure (CHF).
|
{
"A": "Arm Label: Fatigued patients: Immediate start CBT; Type: OTHER; Interventions: Behavioral: immediate CBT | Arm Label: fatigues patients: delayed CBT (after 6 months); Type: OTHER; Interventions: Behavioral: Delayed CBT | Arm Label: non-fatiqued controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: immediate CBT; Assigned to Arm(s): Fatigued patients: Immediate start CBT | Intervention Type: BEHAVIORAL; Name: Delayed CBT; Assigned to Arm(s): fatigues patients: delayed CBT (after 6 months)",
"B": "Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Exercise",
"C": "Arm Label: Telephone Counselling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counselling | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telephone counselling; Assigned to Arm(s): Telephone Counselling",
"D": "Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2"
}
|
D
|
[
"NCT01096641",
"NCT00111865",
"NCT03052777",
"NCT00047437"
] | 535 |
train
|
NCT00047437
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
Brief Summary: The purpose of this study is to determine the long-term safety and effectiveness of exercise training for individuals with congestive heart failure (CHF).
|
{
"A": "Arm Label: Women-Only Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Co-ed Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Home-Based Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation; Assigned to Arm(s): Co-ed Cardiac Rehabilitation, Home-Based Cardiac Rehabilitation, Women-Only Cardiac Rehabilitation",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2",
"C": "Arm Label: Family-Centered Empowerment Model; Type: EXPERIMENTAL; Interventions: Other: Family-centered empowerment model | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Family-centered empowerment model; Assigned to Arm(s): Family-Centered Empowerment Model | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control",
"D": "Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2"
}
|
D
|
[
"NCT01019135",
"NCT00363922",
"NCT02402582",
"NCT00047437"
] | 536 |
train
|
NCT00047437
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
Brief Summary: The purpose of this study is to determine the long-term safety and effectiveness of exercise training for individuals with congestive heart failure (CHF).
|
{
"A": "Arm Label: Family-Centered Empowerment Model; Type: EXPERIMENTAL; Interventions: Other: Family-centered empowerment model | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Family-centered empowerment model; Assigned to Arm(s): Family-Centered Empowerment Model | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control",
"B": "Arm Label: Hospital-based; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Shared care Model; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Shared Care model | Intervention Type: BEHAVIORAL; Name: Shared Care model; Assigned to Arm(s): Shared care Model",
"C": "Arm Label: Learning and coping arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Learning and coping arm | Arm Label: Control arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: Learning and coping arm; Assigned to Arm(s): Learning and coping arm | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm",
"D": "Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2"
}
|
D
|
[
"NCT02402582",
"NCT01522001",
"NCT01668394",
"NCT00047437"
] | 537 |
train
|
NCT00047450
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Citalopram Augmentation in Older Patients With Schizophrenia
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of citalopram (Celexa) for the treatment of depressive symptoms in middle-aged and elderly patients with schizophrenia.
|
{
"A": "Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Citalopram (Celexa) | Intervention Type: DRUG; Name: Citalopram (Celexa); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1",
"B": "Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A",
"C": "Arm Label: Citalopram + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pindolol | Arm Label: Citalopram + pindolol; Type: EXPERIMENTAL; Interventions: Drug: Pindolol | Intervention Type: DRUG; Name: Pindolol; Assigned to Arm(s): Citalopram + pindolol, Citalopram + placebo",
"D": "Arm Label: duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Arm Label: fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: paroxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine | Arm Label: sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: sertraline | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): duloxetine | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): paroxetine | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): sertraline"
}
|
A
|
[
"NCT00047450",
"NCT00021528",
"NCT00931775",
"NCT00666757"
] | 538 |
train
|
NCT00047723
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this trial is to test the safety, tolerability, and effectiveness of minocycline compared to placebo in patients with amyotrophic lateral sclerosis (ALS).
|
{
"A": "Intervention Type: DRUG; Name: Sodium Valproate; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Thalidomide (drug); Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: minocycline; Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium Carbonate, Drug: Riluzole | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Riluzole, Drug: placebo | Intervention Type: DRUG; Name: Lithium Carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2"
}
|
C
|
[
"NCT00136110",
"NCT00231140",
"NCT00047723",
"NCT00818389"
] | 539 |
train
|
NCT00048035
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter, Randomized Study to Determine Dose Conversion Factors at Different Frequencies of Administration After Switching From Maintenance Treatment With Intravenous Epoetin Alfa to Maintenance Treatment With Intravenous RO0503821 in Hemodialysis Patients With Chronic Renal Anemia.
Brief Summary: This study will determine the appropriate dose and frequency of administration of iv Mircera maintenance therapy in hemodialysis patients with chronic renal anemia who were previously receiving iv epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.
|
{
"A": "Arm Label: Cohort 1 (RO0503821 [0.25/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 2 (RO0503821 [0.25/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 3 (RO0503821 [0.4/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 4 (RO0503821 [0.4/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 5 (RO0503821 [0.6/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 6 (RO0503821 [0.6/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): Cohort 1 (RO0503821 [0.25/150 1x/week]), Cohort 2 (RO0503821 [0.25/150 1x/2week]), Cohort 3 (RO0503821 [0.4/150 1x/week]), Cohort 4 (RO0503821 [0.4/150 1x/2week]), Cohort 5 (RO0503821 [0.6/150 1x/week]), Cohort 6 (RO0503821 [0.6/150 1x/2week])",
"B": "Arm Label: HD treated with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Arm Label: post-dilution oHDF with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Arm Label: pre-dilution oHDF with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: HD treated with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: post-dilution oHDF with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: pre-dilution oHDF with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Intervention Type: DEVICE; Name: Citrate dialysate (CiDi); Assigned to Arm(s): HD treated with citrate dialysate, post-dilution oHDF with citrate dialysate, pre-dilution oHDF with citrate dialysate | Intervention Type: DEVICE; Name: Standard dialysate (StDi); Assigned to Arm(s): HD treated with standard dialysate, post-dilution oHDF with standard dialysate, pre-dilution oHDF with standard dialysate",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atenolol | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Lisinopril | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): 1",
"D": "Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00048035",
"NCT01532297",
"NCT00582114",
"NCT00261521"
] | 540 |
train
|
NCT00048425
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.
Brief Summary: The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan compared with placebo in the treatment of decompensated chronic heart failure.
|
{
"A": "Arm Label: Losartan; Type: EXPERIMENTAL; Interventions: Drug: Losartan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): Losartan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"C": "Intervention Type: DRUG; Name: Tilarginine Acetate Injection intravenous infusion; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT01857999",
"NCT00994825",
"NCT00112281",
"NCT00048425"
] | 541 |
train
|
NCT00048542
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis
Brief Summary: This is a multicenter, Phase 3 randomized, placebo-controlled study designed to evaluate adalimumab in children 4 to 17 years old with polyarticular juvenile idiopathic arthritis (JIA) who are either methotrexate (MTX) treated or non-MTX treated.
|
{
"A": "Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Anti-tumor necrosis factor alpha monoclonal antibody | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Anti-tumor necrosis factor alpha monoclonal antibody; Assigned to Arm(s): adalimumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo",
"B": "Arm Label: Double-Blind Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Biological: Double-Blind Adalimumab/Placebo + MTX | Arm Label: Double-Blind Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Biological: Double-Blind Adalimumab/Placebo + MTX | Arm Label: Double-Blind Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-Blind Adalimumab/Placebo | Arm Label: Double-Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Double-Blind Adalimumab/Placebo | Arm Label: OLE BSA Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: OLE BSA Adalimumab +/- MTX | Arm Label: OLE BSA Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: OLE BSA Adalimumab +/- MTX | Arm Label: OLE FD Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: OLE FD Adalimumab +/- MTX | Arm Label: OLE FD Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: OLE FD Adalimumab +/- MTX | Intervention Type: BIOLOGICAL; Name: Double-Blind Adalimumab/Placebo + MTX; Assigned to Arm(s): Double-Blind Adalimumab + MTX, Double-Blind Placebo + MTX | Intervention Type: BIOLOGICAL; Name: Double-Blind Adalimumab/Placebo; Assigned to Arm(s): Double-Blind Adalimumab, Double-Blind Placebo | Intervention Type: DRUG; Name: OLE BSA Adalimumab +/- MTX; Assigned to Arm(s): OLE BSA Adalimumab, OLE BSA Adalimumab + MTX | Intervention Type: DRUG; Name: OLE FD Adalimumab +/- MTX; Assigned to Arm(s): OLE FD Adalimumab, OLE FD Adalimumab + MTX",
"C": "Arm Label: Infliximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Infliximab plus methotrexate | Arm Label: Combination of DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Combination of DMARDs | Arm Label: Methotrexate alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate alone | Intervention Type: DRUG; Name: Infliximab plus methotrexate; Assigned to Arm(s): Infliximab plus Methotrexate | Intervention Type: DRUG; Name: Combination of DMARDs; Assigned to Arm(s): Combination of DMARDs | Intervention Type: DRUG; Name: Methotrexate alone; Assigned to Arm(s): Methotrexate alone",
"D": "Arm Label: Continue adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Stop adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Continue adalimumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Stop adalimumab"
}
|
B
|
[
"NCT01385826",
"NCT00048542",
"NCT01015547",
"NCT03816397"
] | 542 |
train
|
NCT00048568
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Brief Summary: Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied.
Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued.
|
{
"A": "Arm Label: TNF-blocking drug; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Adalimumab, Drug: Certolizumab Pegol, Drug: Infliximab, Drug: Golimumab | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rituximab | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): TNF-blocking drug",
"B": "Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo",
"C": "Arm Label: Placebo Plus Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Other: Placebo | Arm Label: Rituximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: MabThera/Rituxan, Drug: Methotrexate | Intervention Type: DRUG; Name: MabThera/Rituxan; Assigned to Arm(s): Rituximab plus Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo Plus Methotrexate, Rituximab plus Methotrexate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Plus Methotrexate",
"D": "Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate"
}
|
D
|
[
"NCT01295151",
"NCT00580840",
"NCT00468546",
"NCT00048568"
] | 543 |
train
|
NCT00048568
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Brief Summary: Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied.
Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued.
|
{
"A": "Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 5",
"C": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Methylprednisolone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Infliximab | Intervention Type: DRUG; Name: Infliximab, methylprednisolone, methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate + Methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Methotrexate + Infliximab; Assigned to Arm(s): C",
"D": "Arm Label: Rituximab (0.5 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Rituximab (1.0 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: placebo | Intervention Type: DRUG; Name: folate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo + Methotrexate | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate"
}
|
A
|
[
"NCT00048568",
"NCT00713544",
"NCT00396747",
"NCT00299104"
] | 544 |
train
|
NCT00048568
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Brief Summary: Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied.
Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued.
|
{
"A": "Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2",
"C": "Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate",
"D": "Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00085644",
"NCT00554710",
"NCT00048568",
"NCT00235105"
] | 545 |
train
|
NCT00048568
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Brief Summary: Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied.
Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued.
|
{
"A": "Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)",
"B": "Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo",
"C": "Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate",
"D": "Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a"
}
|
C
|
[
"NCT00095147",
"NCT00660647",
"NCT00048568",
"NCT00195494"
] | 546 |
train
|
NCT00048568
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Brief Summary: Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied.
Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3",
"C": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: conventional DMARD combination | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: MTX plus anti-TNF | Intervention Type: DRUG; Name: conventional DMARD combination; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: MTX plus anti-TNF; Assigned to Arm(s): B",
"D": "Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate"
}
|
D
|
[
"NCT00106548",
"NCT00565409",
"NCT00764725",
"NCT00048568"
] | 547 |
train
|
NCT00048568
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Brief Summary: Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied.
Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued.
|
{
"A": "Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3",
"C": "Arm Label: CP-690,550 + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 + methotrexate | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Methotrexate | Intervention Type: DRUG; Name: CP-690,550 + methotrexate; Assigned to Arm(s): CP-690,550 + methotrexate | Intervention Type: DRUG; Name: Placebo + Methotrexate; Assigned to Arm(s): Placebo + methotrexate",
"D": "Arm Label: CP 690,550 1 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 15 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP-690,550 20 mg QD; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 1 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 15 mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 3 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 20 mg QD | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00048568",
"NCT00106548",
"NCT00976599",
"NCT00413660"
] | 548 |
train
|
NCT00048568
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Brief Summary: Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not responding to methotrexate. The safety of this treatment will also be studied.
Long Term Extension: The purpose of this amendment is to provide participants who have completed the initial 12-month double-blind treatment period the opportunity to receive open label treatment with active drug treatment until abatacept is approved in the local country or until clinical development has been discontinued.
|
{
"A": "Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4",
"B": "Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate",
"C": "Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A",
"D": "Arm Label: Tocilizumab 8 mg/kg + DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Permitted DMARDs | Arm Label: Placebo + DMARDs; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Permitted DMARDs | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg + DMARDs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + DMARDs | Intervention Type: DRUG; Name: Permitted DMARDs; Assigned to Arm(s): Placebo + DMARDs, Tocilizumab 8 mg/kg + DMARDs"
}
|
B
|
[
"NCT00847613",
"NCT00048568",
"NCT00548834",
"NCT00531817"
] | 549 |
train
|
NCT00048724
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin
Brief Summary: The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a + Ribavirin, Drug: Peginterferon alfa-2a | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peginterferon alfa-2a + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a + Ribavirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Peginterferon alfa-2a; Assigned to Arm(s): 1",
"B": "Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin | Intervention Type: BIOLOGICAL; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week",
"C": "Arm Label: 1. Placebo + PEG + RBV; Type: PLACEBO_COMPARATOR; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Placebo | Arm Label: 2. Boceprevir + PEG + RBV - 24 Weeks (RGT); Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Arm Label: 3. Boceprevir + PEG + RBV - 44 Weeks; Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2b (PEG); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1. Placebo + PEG + RBV | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks",
"D": "Arm Label: PegIntron; Type: EXPERIMENTAL; Interventions: Biological: peginterferon alfa-2b (SCH 54031) | Arm Label: Untreated Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: peginterferon alfa-2b (SCH 54031); Assigned to Arm(s): PegIntron"
}
|
D
|
[
"NCT00006164",
"NCT00627926",
"NCT00705432",
"NCT00048724"
] | 550 |
train
|
NCT00049517
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation
Brief Summary: RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the transplanted stem cells. When the healthy stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. If the patient's stem cells are to be transplanted, the patient is also treated with a monoclonal antibody, such as gemtuzumab ozogamicin, to kill any remaining cancer cells or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab ozogamicin followed by stem cell transplant in treating acute myeloid leukemia.
PURPOSE: This randomized phase III trial is studying combination chemotherapy, gemtuzumab ozogamicin, and stem cell transplant to see how well they work compared to combination chemotherapy and peripheral stem cell transplant alone in treating patients with acute myeloid leukemia.
|
{
"A": "Intervention Type: DRUG; Name: Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: early allogeneic PBSCT within induction therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous PBSCT; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine, Drug: Idarubicin, Drug: Etoposide, Drug: Pegfilgrastim | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cytarabine, Drug: Idarubicin, Drug: Etoposide, Drug: All-trans retinoic acid, Drug: Pegfilgrastim | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: All-trans retinoic acid; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pegfilgrastim; Assigned to Arm(s): 1, 2",
"C": "Arm Label: Standard Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then Allogeneic HCT or no Consolidation; Type: ACTIVE_COMPARATOR; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Arm Label: High-dose Daunorubicin Then Allogeneic HCT or no Consolidation; Type: EXPERIMENTAL; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Intervention Type: BIOLOGICAL; Name: sargramostim; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: busulfan; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: gemtuzumab ozogamicin (GO); Assigned to Arm(s): High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: Daunorubicin; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Autologous HCT; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Allogeneic HCT; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Allogeneic HCT or no Consolidation",
"D": "Arm Label: Decitabine; Type: EXPERIMENTAL; Interventions: Drug: Decitabine | Arm Label: Decitabine+VPA; Type: EXPERIMENTAL; Interventions: Drug: Decitabine, Drug: VPA | Arm Label: Decitabine+ATRA; Type: EXPERIMENTAL; Interventions: Drug: Decitabine, Drug: ATRA | Arm Label: Decitabine+VPA+ATRA; Type: EXPERIMENTAL; Interventions: Drug: Decitabine, Drug: VPA, Drug: ATRA | Intervention Type: DRUG; Name: Decitabine; Assigned to Arm(s): Decitabine, Decitabine+ATRA, Decitabine+VPA, Decitabine+VPA+ATRA | Intervention Type: DRUG; Name: VPA; Assigned to Arm(s): Decitabine+VPA, Decitabine+VPA+ATRA | Intervention Type: DRUG; Name: ATRA; Assigned to Arm(s): Decitabine+ATRA, Decitabine+VPA+ATRA"
}
|
C
|
[
"NCT00180102",
"NCT00151242",
"NCT00049517",
"NCT00867672"
] | 551 |
train
|
NCT00049517
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation
Brief Summary: RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the transplanted stem cells. When the healthy stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. If the patient's stem cells are to be transplanted, the patient is also treated with a monoclonal antibody, such as gemtuzumab ozogamicin, to kill any remaining cancer cells or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab ozogamicin followed by stem cell transplant in treating acute myeloid leukemia.
PURPOSE: This randomized phase III trial is studying combination chemotherapy, gemtuzumab ozogamicin, and stem cell transplant to see how well they work compared to combination chemotherapy and peripheral stem cell transplant alone in treating patients with acute myeloid leukemia.
|
{
"A": "Arm Label: Standard Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then Allogeneic HCT or no Consolidation; Type: ACTIVE_COMPARATOR; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Arm Label: High-dose Daunorubicin Then Allogeneic HCT or no Consolidation; Type: EXPERIMENTAL; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Intervention Type: BIOLOGICAL; Name: sargramostim; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: busulfan; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: gemtuzumab ozogamicin (GO); Assigned to Arm(s): High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: Daunorubicin; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Autologous HCT; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Allogeneic HCT; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Allogeneic HCT or no Consolidation",
"B": "Arm Label: Cytarabine low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Arm Label: Cytarabine intermediate dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Cytarabine intermediate dose, Cytarabine low dose",
"C": "Intervention Type: DRUG; Name: Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: early allogeneic PBSCT within induction therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous PBSCT; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cytosin-Arabinosid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: All-trans Retinoid acid; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00049517",
"NCT01414231",
"NCT00180102",
"NCT00146120"
] | 552 |
train
|
NCT00049595
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating stage III or stage IV Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have stage III or stage IV Hodgkin's lymphoma.
|
{
"A": "Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Bleomycin, Drug: Etoposide, Drug: Doxorubicin, Drug: Cyclophosphamide, Drug: Vincristine, Drug: Procarbazine, Drug: Prednisone | Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxorubicin, Drug: Bleomycin, Drug: Vinblastine, Drug: Dacarbazine | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Procarbazine; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Arm A",
"B": "Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: BEACOPP-14 chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Arm Label: BEACOPP-escalated chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Arm I, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I, Arm II, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: prednisolone; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: vinblastine sulfate; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy",
"C": "Arm Label: ABVD; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: BEACOPP; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: BEACOPP regimen, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): ABVD, BEACOPP | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): BEACOPP | Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): BEACOPP | Intervention Type: DRUG; Name: ABVD regimen; Assigned to Arm(s): ABVD | Intervention Type: DRUG; Name: BEACOPP regimen; Assigned to Arm(s): BEACOPP | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): BEACOPP | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): ABVD | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): ABVD, BEACOPP | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): BEACOPP | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): BEACOPP | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): BEACOPP | Intervention Type: DRUG; Name: vinblastine sulfate; Assigned to Arm(s): ABVD | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): BEACOPP",
"D": "Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mechlorethamine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vinblastine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT01251107",
"NCT00678327",
"NCT00049595",
"NCT00379041"
] | 553 |
train
|
NCT00049764
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis
Brief Summary: The purposes of this study are to determine:
1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their condition more often or recover faster than children who do not receive drotrecogin alfa (activated).
2. Whether drotrecogin alfa (activated) minimizes long term disabilities associated with severe sepsis.
3. The side effects that might be associated with drotrecogin alfa (activated) administration to children with severe sepsis.
|
{
"A": "Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"C": "Intervention Type: DRUG; Name: Drotrecogin Alfa (Activated); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): N/A",
"D": "Arm Label: Drotrecogin alfa (activated); Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
B
|
[
"NCT00625209",
"NCT00049764",
"NCT00049777",
"NCT00604214"
] | 554 |
train
|
NCT00049777
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Heparin in Patients With Severe Sepsis and Higher Disease Severity Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)
Brief Summary: The purpose of this study is to evaluate the relative efficacy and safety of prophylactic heparin co-administration during drotrecogin alfa (activated) infusion in the treatment of severe sepsis in the adult.
|
{
"A": "Arm Label: Drotrecogin alfa (activated); Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4",
"C": "Arm Label: Standard therapy; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:moderate protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:severe protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Alternative therapy:moderate protein C deficiency, Alternative therapy:severe protein C deficiency, Standard therapy",
"D": "Intervention Type: DRUG; Name: Drotrecogin Alfa (Activated); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00604214",
"NCT00625209",
"NCT00386425",
"NCT00049777"
] | 555 |
train
|
NCT00049829
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HORIZON-PFT: Pivotal Fracture Trial
Brief Summary: HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.
|
{
"A": "Arm Label: Zoledronic Acid 2x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Zoledronic Acid 1x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): Zoledronic Acid 1x5 mg, Zoledronic Acid 2x5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Zoledronic Acid 1x5 mg",
"B": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M",
"D": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00132808",
"NCT00049829",
"NCT00089791",
"NCT00100620"
] | 556 |
train
|
NCT00049829
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HORIZON-PFT: Pivotal Fracture Trial
Brief Summary: HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.
|
{
"A": "Arm Label: rosiglitazone in addition to background metformin; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Metformin | Arm Label: rosiglitazone in addition to background sulfonylurea; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Sulfonylurea | Arm Label: Sulfonylurea in addition to background metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Arm Label: Metformin in addition to background sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): rosiglitazone in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background metformin",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Arzoxifene | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arzoxifene; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"C": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00379769",
"NCT00088010",
"NCT00000611",
"NCT00049829"
] | 557 |
train
|
NCT00049829
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HORIZON-PFT: Pivotal Fracture Trial
Brief Summary: HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.
|
{
"A": "Arm Label: Zoledronic Acid 2x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid | Arm Label: Zoledronic Acid 1x5 mg; Type: EXPERIMENTAL; Interventions: Drug: Zoledronic Acid, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): Zoledronic Acid 1x5 mg, Zoledronic Acid 2x5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Zoledronic Acid 1x5 mg",
"B": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00132808",
"NCT00046254",
"NCT00049829",
"NCT00097825"
] | 558 |
train
|
NCT00050479
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preliminary Multi-Center Assessment of Laser and Medical Treatment of Diabetic Macular Edema
Brief Summary: This study will compare the side effects of two laser treatments for diabetic macular edema, a common condition in patients with diabetes. In macular edema, blood vessels in the retina, a thin layer of tissue that lines the back of the eye become leaky and the retina swells. The macula, the center part of the retina that is responsible for fine vision may also swell, causing vision loss. Traditional laser treatment (argon blue or green or yellow) for macular swelling, or edema, causes scarring that can expand and possibly lead to more loss of vision. Studies with a different type of laser (diode) may be less damaging. The results of this study on side effects of the treatments will be used to design a larger study of effectiveness. This study will also examine whether celecoxib (Celebrex® (Registered Trademark)), an anti-arthritis drug that reduces inflammation and swelling, can reduce inflammation and swelling of the retina. Patients with elevated cholesterol levels will be invited to participate in a cholesterol reduction part of the study to compare normal-pace cholesterol reduction with accelerated reduction.
Patients 18 years of age and older with type 1 or type 2 diabetes and macular edema that requires laser treatment may be eligible for this study. Candidates will be screened with the following tests and procedures:
* Medical history: to review past medical conditions and treatments.
* Physical examination: to measure vital signs (pulse, blood pressure, temperature, breathing rate) and examine the head and neck, heart, lungs, abdomen, arms and legs.
* Eye examination: to assess visual acuity (eye chart test) and examine pupils, lens, retina, and eye movements. The pupils will be dilated with drops for this examination.
* Blood tests: to measure cholesterol, blood clotting time, hemoglobin A1C (a measure of diabetes control), and to evaluate liver and kidney function.
* Eye photography: to help evaluate the status of the retina and changes that may occur in the future. Special photographs of the inside of the eye are taken using a camera that flashes a bright light into the eye. From 2 to 20 pictures may be taken, depending on the eye condition.
* Fluorescein angiography: to evaluate the eye's blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality.
Participants will be randomly assigned to take celecoxib or placebo (an inactive, look-alike pill). Participants who have elevated cholesterol levels may return for a brief visit after 1 month. All patients will return for follow-up visits at 3, 6, and 12 months. Patients who require laser treatment will be randomly assigned to one of the two laser treatments. For these procedures, eye drops are put in the eye to numb the surface and a contact lens is placed on the eye during the laser beam application. Several visits may be required for additional laser treatments. The maximum number of treatments depends on how well the treatment is working. Patients who respond well to the study medication may receive no laser treatments. After the first year, patients will be followed every 6 months until either the patient returns for a 3-year visit, the last enrolled patient returns for the 1-year visit, or the patient requests to leave the study. During the follow-up visits, patients' response to treatment will be evaluated with repeat tests of several of the screening exams.
|
{
"A": "Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): N/A",
"B": "Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo",
"C": "Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Celecoxib | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A",
"D": "Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00432081",
"NCT00153062",
"NCT00141193",
"NCT00050479"
] | 559 |
train
|
NCT00050557
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Psychoeducation: Efficacy in Child Mood Disorders
Brief Summary: The purpose of this study is to evaluate the effectiveness of a Multifamily Psychoeducation Group for the families of children with mood disorders.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT), Drug: Drug therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Drug therapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug therapy; Assigned to Arm(s): 1, 2",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Multifamily Psychoeducation Group (MFPG); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine (Prozac) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus Treatment As Usual | Intervention Type: DRUG; Name: fluoxetine (Prozac); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo plus Treatment As Usual; Assigned to Arm(s): 2",
"D": "Arm Label: Active, 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Active, 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo"
}
|
B
|
[
"NCT00158301",
"NCT00050557",
"NCT00027378",
"NCT00508859"
] | 560 |
train
|
NCT00050778
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Brief Summary: This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis (MS) who had not been previously treated with MS therapies other than steroids. The study was conducted for an initial period of 3 years and a follow-up to 5 years or more.
|
{
"A": "Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM",
"B": "Arm Label: Placebo-Controlled Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Active Treatment Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Off Drug; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Active Treatment Phase: Laquinimod 1.2 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 1.2 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Placebo",
"C": "Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012, Drug: Placebo | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 240 mg Twice Daily (BID), Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)",
"D": "Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg"
}
|
D
|
[
"NCT01064401",
"NCT01707992",
"NCT00451451",
"NCT00050778"
] | 561 |
train
|
NCT00050778
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Brief Summary: This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis (MS) who had not been previously treated with MS therapies other than steroids. The study was conducted for an initial period of 3 years and a follow-up to 5 years or more.
|
{
"A": "Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg",
"B": "Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg",
"C": "Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A",
"D": "Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00050778",
"NCT00751881",
"NCT00168701",
"NCT00134563"
] | 562 |
train
|
NCT00050778
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Brief Summary: This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis (MS) who had not been previously treated with MS therapies other than steroids. The study was conducted for an initial period of 3 years and a follow-up to 5 years or more.
|
{
"A": "Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®",
"B": "Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo",
"D": "Arm Label: DAC HYP; Type: EXPERIMENTAL; Interventions: Drug: Midazolam, Other: Caffeine, Drug: S-warfarin, Other: Vitamin K, Drug: Omeprazole, Drug: Dextromethorphan, Biological: BIIB019 (Daclizumab) | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): DAC HYP | Intervention Type: OTHER; Name: Caffeine; Assigned to Arm(s): DAC HYP | Intervention Type: DRUG; Name: S-warfarin; Assigned to Arm(s): DAC HYP | Intervention Type: OTHER; Name: Vitamin K; Assigned to Arm(s): DAC HYP | Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): DAC HYP | Intervention Type: DRUG; Name: Dextromethorphan; Assigned to Arm(s): DAC HYP | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab); Assigned to Arm(s): DAC HYP"
}
|
B
|
[
"NCT00078338",
"NCT00050778",
"NCT00906399",
"NCT01462318"
] | 563 |
train
|
NCT00050817
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.
Brief Summary: RATIONALE:
* Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
* In patients at risk for this disease, it is characterized by an unpredictable, sudden disruption of atherosclerotic plaques, which may lead to total occlusion of artery due to formation of a clot. The use of aspirin (blood thinner agent) for reducing those major ischemic events is either indicated, or recommended by international guidelines. However, aspirin fails to prevent a high percentage of such life-threatening events. Therefore, more effective blood thinning therapy may provide additional clinical benefit to such patients.
* The results of the CURE trial in patients with unstable angina demonstrate the additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood thinner agent), when administered in combination with standard therapy including aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of clopidogrel may apply to a broad population of high-risk patients receiving low-dose aspirin therapy. Such population includes patients with previous cardiovascular, neurovascular or peripheral arterial manifestations of atherothrombosis and patients with combinations of recognized risk factors for atherosclerosis.
OBJECTIVES:
* To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in preventing cardiovascular morbidity/mortality. The study will compare the efficacy of the two regimens in preventing the occurrence of major cardiovascular complications (stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise receiving low-dose aspirin therapy (75-162 mg daily).
* To evaluate the safety of clopidogrel in this population, and more specifically the incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate the global benefit of clopidogrel in this patient population.
|
{
"A": "Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: clopidogrel and metoprolol; Assigned to Arm(s): N/A",
"C": "Arm Label: Beta-blocker adherence after an AMI; Type: EXPERIMENTAL; Interventions: Behavioral: Beta-blocker adherence after an AMI | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Beta-blocker adherence after an AMI; Assigned to Arm(s): Beta-blocker adherence after an AMI",
"D": "Arm Label: Beta blocker treatment; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol Succinate, Drug: Bisoprolol, Drug: Carvedilol, Drug: Nebivolol | Arm Label: No beta blocker treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Metoprolol Succinate; Assigned to Arm(s): Beta blocker treatment | Intervention Type: DRUG; Name: Bisoprolol; Assigned to Arm(s): Beta blocker treatment | Intervention Type: DRUG; Name: Carvedilol; Assigned to Arm(s): Beta blocker treatment | Intervention Type: DRUG; Name: Nebivolol; Assigned to Arm(s): Beta blocker treatment"
}
|
A
|
[
"NCT00050817",
"NCT00222573",
"NCT00211172",
"NCT03778554"
] | 564 |
train
|
NCT00050817
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.
Brief Summary: RATIONALE:
* Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
* In patients at risk for this disease, it is characterized by an unpredictable, sudden disruption of atherosclerotic plaques, which may lead to total occlusion of artery due to formation of a clot. The use of aspirin (blood thinner agent) for reducing those major ischemic events is either indicated, or recommended by international guidelines. However, aspirin fails to prevent a high percentage of such life-threatening events. Therefore, more effective blood thinning therapy may provide additional clinical benefit to such patients.
* The results of the CURE trial in patients with unstable angina demonstrate the additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood thinner agent), when administered in combination with standard therapy including aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of clopidogrel may apply to a broad population of high-risk patients receiving low-dose aspirin therapy. Such population includes patients with previous cardiovascular, neurovascular or peripheral arterial manifestations of atherothrombosis and patients with combinations of recognized risk factors for atherosclerosis.
OBJECTIVES:
* To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in preventing cardiovascular morbidity/mortality. The study will compare the efficacy of the two regimens in preventing the occurrence of major cardiovascular complications (stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise receiving low-dose aspirin therapy (75-162 mg daily).
* To evaluate the safety of clopidogrel in this population, and more specifically the incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate the global benefit of clopidogrel in this patient population.
|
{
"A": "Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo",
"B": "Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: standard medication; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin",
"C": "Intervention Type: DEVICE; Name: Renal Artery Stent with Protective Device/Drug; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00979589",
"NCT01709994",
"NCT00234585",
"NCT00050817"
] | 565 |
train
|
NCT00050817
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.
Brief Summary: RATIONALE:
* Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
* In patients at risk for this disease, it is characterized by an unpredictable, sudden disruption of atherosclerotic plaques, which may lead to total occlusion of artery due to formation of a clot. The use of aspirin (blood thinner agent) for reducing those major ischemic events is either indicated, or recommended by international guidelines. However, aspirin fails to prevent a high percentage of such life-threatening events. Therefore, more effective blood thinning therapy may provide additional clinical benefit to such patients.
* The results of the CURE trial in patients with unstable angina demonstrate the additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood thinner agent), when administered in combination with standard therapy including aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of clopidogrel may apply to a broad population of high-risk patients receiving low-dose aspirin therapy. Such population includes patients with previous cardiovascular, neurovascular or peripheral arterial manifestations of atherothrombosis and patients with combinations of recognized risk factors for atherosclerosis.
OBJECTIVES:
* To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in preventing cardiovascular morbidity/mortality. The study will compare the efficacy of the two regimens in preventing the occurrence of major cardiovascular complications (stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise receiving low-dose aspirin therapy (75-162 mg daily).
* To evaluate the safety of clopidogrel in this population, and more specifically the incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate the global benefit of clopidogrel in this patient population.
|
{
"A": "Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel",
"B": "Arm Label: Cangrelor; Type: EXPERIMENTAL; Interventions: Drug: Cangrelor (P2Y12 inhibitor), Drug: clopidogrel (oral P2Y12 inhibitor), Drug: Placebo capsules - as soon as possible after randomization | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel (oral P2Y12 inhibitor), Drug: Placebo bolus & placebo infusion, Drug: Placebo capsules - end of infusion | Intervention Type: DRUG; Name: Cangrelor (P2Y12 inhibitor); Assigned to Arm(s): Cangrelor | Intervention Type: DRUG; Name: clopidogrel (oral P2Y12 inhibitor); Assigned to Arm(s): Cangrelor, Clopidogrel | Intervention Type: DRUG; Name: Placebo bolus & placebo infusion; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Placebo capsules - end of infusion; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Placebo capsules - as soon as possible after randomization; Assigned to Arm(s): Cangrelor",
"C": "Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A",
"D": "Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet"
}
|
C
|
[
"NCT00391872",
"NCT00305162",
"NCT00050817",
"NCT00059306"
] | 566 |
train
|
NCT00050817
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.
Brief Summary: RATIONALE:
* Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
* In patients at risk for this disease, it is characterized by an unpredictable, sudden disruption of atherosclerotic plaques, which may lead to total occlusion of artery due to formation of a clot. The use of aspirin (blood thinner agent) for reducing those major ischemic events is either indicated, or recommended by international guidelines. However, aspirin fails to prevent a high percentage of such life-threatening events. Therefore, more effective blood thinning therapy may provide additional clinical benefit to such patients.
* The results of the CURE trial in patients with unstable angina demonstrate the additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood thinner agent), when administered in combination with standard therapy including aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of clopidogrel may apply to a broad population of high-risk patients receiving low-dose aspirin therapy. Such population includes patients with previous cardiovascular, neurovascular or peripheral arterial manifestations of atherothrombosis and patients with combinations of recognized risk factors for atherosclerosis.
OBJECTIVES:
* To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in preventing cardiovascular morbidity/mortality. The study will compare the efficacy of the two regimens in preventing the occurrence of major cardiovascular complications (stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise receiving low-dose aspirin therapy (75-162 mg daily).
* To evaluate the safety of clopidogrel in this population, and more specifically the incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate the global benefit of clopidogrel in this patient population.
|
{
"A": "Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A",
"C": "Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin monotherapy | Arm Label: Aspirin,Clopidogrel; Type: EXPERIMENTAL; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin monotherapy; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin Tablets | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel (over encapsulated) capsule, Drug: Aspirin Tablets | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor Tablets, Drug: Aspirin Tablets | Intervention Type: DRUG; Name: Ticagrelor Tablets; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Clopidogrel (over encapsulated) capsule; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Aspirin Tablets; Assigned to Arm(s): 1, 2, 3"
}
|
A
|
[
"NCT00050817",
"NCT00109382",
"NCT00484926",
"NCT00528411"
] | 567 |
train
|
NCT00050817
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.
Brief Summary: RATIONALE:
* Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
* In patients at risk for this disease, it is characterized by an unpredictable, sudden disruption of atherosclerotic plaques, which may lead to total occlusion of artery due to formation of a clot. The use of aspirin (blood thinner agent) for reducing those major ischemic events is either indicated, or recommended by international guidelines. However, aspirin fails to prevent a high percentage of such life-threatening events. Therefore, more effective blood thinning therapy may provide additional clinical benefit to such patients.
* The results of the CURE trial in patients with unstable angina demonstrate the additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood thinner agent), when administered in combination with standard therapy including aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of clopidogrel may apply to a broad population of high-risk patients receiving low-dose aspirin therapy. Such population includes patients with previous cardiovascular, neurovascular or peripheral arterial manifestations of atherothrombosis and patients with combinations of recognized risk factors for atherosclerosis.
OBJECTIVES:
* To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in preventing cardiovascular morbidity/mortality. The study will compare the efficacy of the two regimens in preventing the occurrence of major cardiovascular complications (stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise receiving low-dose aspirin therapy (75-162 mg daily).
* To evaluate the safety of clopidogrel in this population, and more specifically the incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate the global benefit of clopidogrel in this patient population.
|
{
"A": "Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel",
"B": "Intervention Type: DRUG; Name: anticoagulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin and dipyridamole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin alone; Assigned to Arm(s): N/A",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 | Intervention Type: DRUG; Name: Warfarin titrated to an INR of 2.5-3.0; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Clopidogrel 75; Assigned to Arm(s): 3",
"D": "Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00097591",
"NCT00161070",
"NCT00007683",
"NCT00050817"
] | 568 |
train
|
NCT00051298
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
Brief Summary: This study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of schizophrenia in adolescents. Both the potential benefits and side effects of olanzapine will be evaluated throughout this trial.
|
{
"A": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A",
"C": "Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone",
"D": "Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group"
}
|
A
|
[
"NCT00051298",
"NCT00034749",
"NCT00053703",
"NCT00102063"
] | 569 |
train
|
NCT00051467
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer
Brief Summary: The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic cancer.
TNFerade™ is a replication deficient adenovirus vector containing the gene for TNF-alpha controlled by a chemoradiation inducible promoter. This allows the expression of TNF-alpha to be greatest in the area receiving radiation. TNF-alpha is a cytokine that has been shown to have potent anti-cancer activities but, due to systemic toxicity, could not be delivered at effective doses. TNFerade™ Biologic is a novel way of selective delivery of TNF-alpha to tumor cells.
TNFerade™ Biologic will be injected during five weekly injection sessions, concomitant with radiation and 5-FU. TNFerade™ Biologic will be administered by direct intratumoral injection using a percutaneous approach (PTA) or endoscopic ultrasound (EUS).
|
{
"A": "Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: fluorouracil, Radiation: radiation therapy | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: docetaxel, Radiation: radiation therapy | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm 1 | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1, Arm 2",
"B": "Arm Label: 5-FU & LV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Leucovorin, Drug: 5-Fluorouracil | Arm Label: XELOX or modified FOLFOX-6; Type: EXPERIMENTAL; Interventions: Drug: Leucovorin, Drug: OXALIPLATIN, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): 5-FU & LV, XELOX or modified FOLFOX-6 | Intervention Type: DRUG; Name: OXALIPLATIN; Assigned to Arm(s): XELOX or modified FOLFOX-6 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 5-FU & LV, XELOX or modified FOLFOX-6",
"C": "Intervention Type: GENETIC; Name: TNFerade; Assigned to Arm(s): N/A",
"D": "Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Erlotinib | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Erlotinib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A, Arm B"
}
|
C
|
[
"NCT00112697",
"NCT01121848",
"NCT00051467",
"NCT00440167"
] | 570 |
train
|
NCT00052065
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Brief Summary: This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.
|
{
"A": "Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin",
"B": "Intervention Type: DRUG; Name: TLK286; Assigned to Arm(s): N/A",
"C": "Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin",
"D": "Arm Label: Vintafolide + PLD; Type: EXPERIMENTAL; Interventions: Drug: Vintafolide, Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Arm Label: PLD Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Intervention Type: DRUG; Name: Vintafolide; Assigned to Arm(s): Vintafolide + PLD | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD Alone, Vintafolide + PLD | Intervention Type: OTHER; Name: EC20; Assigned to Arm(s): PLD Alone, Vintafolide + PLD"
}
|
B
|
[
"NCT00113607",
"NCT00052065",
"NCT00350948",
"NCT00722592"
] | 571 |
train
|
NCT00052078
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Child/Adolescent Anxiety Multimodal Treatment Study
Brief Summary: This randomized, controlled trial compared the efficacy of the medication sertraline (Zoloft®), cognitive-behavioral therapy, the combination of these treatments, and placebo for youth with anxiety disorders.
|
{
"A": "Arm Label: Social Effectiveness Therapy for Children; Type: EXPERIMENTAL; Interventions: Behavioral: Social Effectiveness Therapy for Children (SET-C) | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Pill placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pill Placebo | Intervention Type: BEHAVIORAL; Name: Social Effectiveness Therapy for Children (SET-C); Assigned to Arm(s): Social Effectiveness Therapy for Children | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Pill Placebo; Assigned to Arm(s): Pill placebo",
"B": "Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Cat cognitive-behavioral therapy for anxious youth | Arm Label: Waitlist Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coping Cat cognitive-behavioral therapy for anxious youth; Assigned to Arm(s): CBT",
"C": "Arm Label: Usual Care Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: psychotherapy | Arm Label: Standard Manual Treatment (SMT); Type: EXPERIMENTAL; Interventions: Behavioral: evidence-based treatment | Arm Label: Modular Maual Treatment (MMT); Type: EXPERIMENTAL; Interventions: Behavioral: modular evidence-based treatment | Intervention Type: BEHAVIORAL; Name: psychotherapy; Assigned to Arm(s): Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: evidence-based treatment; Assigned to Arm(s): Standard Manual Treatment (SMT) | Intervention Type: BEHAVIORAL; Name: modular evidence-based treatment; Assigned to Arm(s): Modular Maual Treatment (MMT)",
"D": "Arm Label: Sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT) | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: SRT + CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT), Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline (SRT); Assigned to Arm(s): SRT + CBT, Sertraline | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT, SRT + CBT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
D
|
[
"NCT00043537",
"NCT01187784",
"NCT01178554",
"NCT00052078"
] | 572 |
train
|
NCT00052078
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Child/Adolescent Anxiety Multimodal Treatment Study
Brief Summary: This randomized, controlled trial compared the efficacy of the medication sertraline (Zoloft®), cognitive-behavioral therapy, the combination of these treatments, and placebo for youth with anxiety disorders.
|
{
"A": "Arm Label: Cognitive Behavioral Therapy Condition; Type: EXPERIMENTAL; Interventions: Other: Cognitive Behavioral Therapy | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: OTHER; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy Condition | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Treatment as Usual",
"B": "Arm Label: 1. Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: 2. Client Centered Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Client Centered Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): 1. Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Client Centered Therapy; Assigned to Arm(s): 2. Client Centered Therapy",
"C": "Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: family based cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: family based cognitive behavior therapy; Assigned to Arm(s): 2",
"D": "Arm Label: Sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT) | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: SRT + CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT), Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline (SRT); Assigned to Arm(s): SRT + CBT, Sertraline | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT, SRT + CBT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
D
|
[
"NCT01563003",
"NCT00774150",
"NCT00255112",
"NCT00052078"
] | 573 |
train
|
NCT00052091
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PST in Geriatric Depression With Executive Dysfunction
Brief Summary: This study will compare the effectiveness of Problem Solving Therapy and Brief Supportive Therapy in treating elderly patients with major depression and thought problems.
|
{
"A": "Arm Label: Interpersonal Psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Psychotherapy, Behavioral: Psychoeducational Group Therapy | Arm Label: Psychoeducational Group Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Psychotherapy, Behavioral: Psychoeducational Group Therapy | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): Interpersonal Psychotherapy, Psychoeducational Group Therapy | Intervention Type: BEHAVIORAL; Name: Psychoeducational Group Therapy; Assigned to Arm(s): Interpersonal Psychotherapy, Psychoeducational Group Therapy",
"B": "Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A",
"C": "Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2 Brief Supportive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: BEHAVIORAL; Name: Brief Supportive Therapy; Assigned to Arm(s): 2 Brief Supportive Therapy",
"D": "Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: desvenlafaxine succinate sustained release | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Genetic: Genotyping | Intervention Type: DRUG; Name: desvenlafaxine succinate sustained release; Assigned to Arm(s): 1 | Intervention Type: GENETIC; Name: Genotyping; Assigned to Arm(s): 2"
}
|
C
|
[
"NCT02314767",
"NCT01360632",
"NCT00052091",
"NCT00824291"
] | 574 |
train
|
NCT00052091
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PST in Geriatric Depression With Executive Dysfunction
Brief Summary: This study will compare the effectiveness of Problem Solving Therapy and Brief Supportive Therapy in treating elderly patients with major depression and thought problems.
|
{
"A": "Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2 Brief Supportive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: BEHAVIORAL; Name: Brief Supportive Therapy; Assigned to Arm(s): 2 Brief Supportive Therapy",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to interest | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to function | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to both interest and function | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Activity matched to interest; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Activity matched to function; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Activity matched to both interest and function; Assigned to Arm(s): 3",
"C": "Intervention Type: BEHAVIORAL; Name: support groups; Assigned to Arm(s): N/A",
"D": "Arm Label: Behavior Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation (BA) | Arm Label: Supportive Therapy (ST); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Therapy (ST) | Intervention Type: BEHAVIORAL; Name: Behavioral Activation (BA); Assigned to Arm(s): Behavior Activation | Intervention Type: BEHAVIORAL; Name: Supportive Therapy (ST); Assigned to Arm(s): Supportive Therapy (ST)"
}
|
A
|
[
"NCT00052091",
"NCT00388544",
"NCT00285753",
"NCT01299766"
] | 575 |
train
|
NCT00053560
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
Brief Summary: The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).
|
{
"A": "Arm Label: real drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dehydroepiandrosterone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dehydroepiandrosterone; Assigned to Arm(s): real drug | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo",
"B": "Intervention Type: DRUG; Name: Prasterone (GL701); Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Prasterone (GL701); Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00916396",
"NCT00053560",
"NCT00082511",
"NCT00000611"
] | 576 |
train
|
NCT00053703
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Schizophrenia and Related Disorders in Children and Adolescents
Brief Summary: This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.
|
{
"A": "Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone",
"B": "Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A",
"C": "Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Family-aided Assertive Community Treatment; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Behavioral: Psychoeducational multifamily group treatment, Behavioral: Supported employment and education | Intervention Type: DRUG; Name: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Psychoeducational multifamily group treatment; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Supported employment and education; Assigned to Arm(s): Family-aided Assertive Community Treatment",
"D": "Arm Label: In SHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: In SHAPE, Behavioral: Fitness Club Membership | Arm Label: Fitness Club Membership; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fitness Club Membership | Intervention Type: BEHAVIORAL; Name: In SHAPE; Assigned to Arm(s): In SHAPE | Intervention Type: BEHAVIORAL; Name: Fitness Club Membership; Assigned to Arm(s): Fitness Club Membership, In SHAPE"
}
|
A
|
[
"NCT00053703",
"NCT00034749",
"NCT00531518",
"NCT02090335"
] | 577 |
train
|
NCT00053703
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Schizophrenia and Related Disorders in Children and Adolescents
Brief Summary: This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.
|
{
"A": "Arm Label: Melatonin; Type: EXPERIMENTAL; Interventions: Drug: Melatonin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): Melatonin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone",
"C": "Arm Label: metformin 500 mg/d; clozapine 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Arm Label: metformin 1000 mg/d; clozapine 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Arm Label: placebo; clozapine 100 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Intervention Type: DRUG; Name: metformin 500 mg; Assigned to Arm(s): metformin 1000 mg/d; clozapine 100 mg, metformin 500 mg/d; clozapine 100 mg, placebo; clozapine 100 mg | Intervention Type: DRUG; Name: clozapine 100 mg; Assigned to Arm(s): metformin 1000 mg/d; clozapine 100 mg, metformin 500 mg/d; clozapine 100 mg, placebo; clozapine 100 mg",
"D": "Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Behavioral: Wellness education | Arm Label: Olanzapine + Amantadine; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Drug: amantadine, Drug: metformin, Drug: zonisamide, Behavioral: Wellness education | Arm Label: Olanzapine + Metformin; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Drug: amantadine, Drug: metformin, Drug: zonisamide, Behavioral: Wellness education | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine, Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: amantadine; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: zonisamide; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: BEHAVIORAL; Name: Wellness education; Assigned to Arm(s): Olanzapine, Olanzapine + Amantadine, Olanzapine + Metformin"
}
|
B
|
[
"NCT01593774",
"NCT00053703",
"NCT02751307",
"NCT00401973"
] | 578 |
train
|
NCT00053703
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Schizophrenia and Related Disorders in Children and Adolescents
Brief Summary: This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.
|
{
"A": "Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone",
"B": "Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group",
"C": "Intervention Type: DRUG; Name: Quetiapine Fumarate; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00053703",
"NCT00102063",
"NCT00449397",
"NCT00051298"
] | 579 |
train
|
NCT00054392
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating non-small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
|
{
"A": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A",
"B": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Monotherapy (gemcitabine or vinorelbine) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Monotherapy (gemcitabine or vinorelbine); Assigned to Arm(s): A",
"C": "Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Carboplatin | Arm Label: Arm A:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm A:, Arm B | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B",
"D": "Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vinorelbine tartrate; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00054392",
"NCT00298415",
"NCT01836575",
"NCT00079287"
] | 580 |
train
|
NCT00054613
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Single-Blind Study of Extracorporeal Photoimmune Therapy With UVADEX in Conjunction With Standard Therapy Alone for the Treatment of Patients With Corticosteroid-Refractory, Corticosteroid-Dependent, or Corticosteroid-Intolerant Chronic Graft-versus-Host Disease
Brief Summary: The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).
|
{
"A": "Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"B": "Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Methoxsalen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Extracorporeal Photopheresis; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00089141",
"NCT00136396",
"NCT00054613",
"NCT00144430"
] | 581 |
train
|
NCT00054613
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Single-Blind Study of Extracorporeal Photoimmune Therapy With UVADEX in Conjunction With Standard Therapy Alone for the Treatment of Patients With Corticosteroid-Refractory, Corticosteroid-Dependent, or Corticosteroid-Intolerant Chronic Graft-versus-Host Disease
Brief Summary: The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).
|
{
"A": "Intervention Type: DRUG; Name: Methoxsalen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Extracorporeal Photopheresis; Assigned to Arm(s): N/A",
"B": "Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"C": "Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A",
"D": "N/A"
}
|
A
|
[
"NCT00054613",
"NCT00089141",
"NCT00136396",
"NCT00637689"
] | 582 |
train
|
NCT00054704
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression
Brief Summary: This study examines if Riluzole, FDA approved for ALS, will improve symptoms of depression in Bipolar Disorder.
Purpose: This study will examine the safety and effectiveness of riluzole (Rilutek trademark) for short-term treatment of depression symptoms, such as depressed mood, psychomotor retardation, and excessive sleeping in patients with bipolar disease. Riluzole is approved by the Food and Drug Administration (FDA) to treat amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). Preliminary findings of a study using riluzole to treat acute depression in patients with unipolar depression indicate that it may have antidepressant properties in some patients.
Patients between 18 and 70 years of age with bipolar I or II disorder without psychosis may be eligible for this 8-week study. Candidates must be currently depressed, must have had at least one previous major depressive episode, and must have failed to improve with prior treatment with at least one antidepressant. They will be screened with a medical history, physical examination, electrocardiogram (EKG), blood and urine tests, and psychiatric evaluation. A blood or urine sample will be analyzed for illegal drugs. Women of childbearing potential will have a pregnancy test.
Participants will begin an 8-week course of treatment, starting with a placebo (a sugar pill formulated to look like the active drug) and, at some point, switching to riluzole. In addition to drug treatment, participants will undergo the following procedures:
Physical examination and electrocardiogram (EKG) at the beginning and end of the study;
Weekly check of vital signs (temperature, blood pressure and heart rate);
Weekly 1-hour interviews consisting of psychiatric and psychomotor rating scales to assess treatment response;
Weekly blood tests to measure blood levels of riluzole and evaluate drug side effects.
At the end of the study, participants' psychiatric status will be reassessed and appropriate long-term psychiatric treatment arranged.
Atendemos pacientes de habla hispana.
We enroll eligible participants locally and from around the country. Travel arrangements are provided and costs covered by the National Institute of Mental Health (NIMH). (Arrangements vary by distance and by specific study.) After completing the study participants receive short-term follow-up care while transitioning back to a provider.
|
{
"A": "Arm Label: A: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: B: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): A: Ketamine + Naltrexone or placebo, B: Ketamine + Naltrexone or placebo",
"B": "Arm Label: Patients with bipolar disorder; Type: N/A; Interventions: N/A | Arm Label: Healthy first generation relatives; Type: N/A; Interventions: N/A | Arm Label: Healthy individuals; Type: N/A; Interventions: N/A",
"C": "Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: N-acetyl-cysteine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: N-acetyl-cysteine (NAC) | Arm Label: Aspirin and NAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Dietary Supplement: N-acetyl-cysteine (NAC) | Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sugar Pill | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin, Aspirin and NAC | Intervention Type: DIETARY_SUPPLEMENT; Name: N-acetyl-cysteine (NAC); Assigned to Arm(s): Aspirin and NAC, N-acetyl-cysteine | Intervention Type: DRUG; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill",
"D": "Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
D
|
[
"NCT02911597",
"NCT02888262",
"NCT01797575",
"NCT00054704"
] | 583 |
train
|
NCT00054782
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Insulin
Brief Summary: This 24-week study will compare the effects of adding the drug rosiglitazone (2mg and 4mg) or placebo to insulin in patients with Type 2 diabetes mellitus (non-insulin-dependent) who have not achieved their blood glucose goal using insulin alone. This study requires a total of seven visits during 28 weeks.
|
{
"A": "Arm Label: Saxagliptin, 5 mg + insulin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, 5 mg + insulin | Arm Label: Placebo + insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + insulin | Intervention Type: DRUG; Name: Saxagliptin, 5 mg + insulin; Assigned to Arm(s): Saxagliptin, 5 mg + insulin | Intervention Type: DRUG; Name: Placebo + insulin; Assigned to Arm(s): Placebo + insulin",
"B": "Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A",
"C": "Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control"
}
|
B
|
[
"NCT00757588",
"NCT00054782",
"NCT01582230",
"NCT00032487"
] | 584 |
train
|
NCT00054925
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Loss Maintenance (WLM)
Brief Summary: To determine the effectiveness of continuous patient contact on weight loss maintenance.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: group sessions, Drug: sibutramine, orlistat, diethylpropion, Behavioral: Low Calorie Diet, Health One, Other: Intensive Medical Combination Therapy for Obesity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Condition | Intervention Type: BEHAVIORAL; Name: group sessions; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sibutramine, orlistat, diethylpropion; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet, Health One; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Intensive Medical Combination Therapy for Obesity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control Condition; Assigned to Arm(s): 2",
"B": "Arm Label: E1; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Care | Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individualized IC treatment | Intervention Type: BEHAVIORAL; Name: Individualized IC treatment; Assigned to Arm(s): A1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): E1",
"C": "Arm Label: Personal contact (PC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Personal contact (PC) | Arm Label: Interactive technology (IT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive technology (IT) | Intervention Type: BEHAVIORAL; Name: Personal contact (PC); Assigned to Arm(s): Personal contact (PC) | Intervention Type: BEHAVIORAL; Name: Interactive technology (IT); Assigned to Arm(s): Interactive technology (IT)",
"D": "Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: control; Type: EXPERIMENTAL; Interventions: Other: control group | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle intervention | Intervention Type: OTHER; Name: control group; Assigned to Arm(s): control"
}
|
C
|
[
"NCT00115063",
"NCT00750022",
"NCT00054925",
"NCT00417599"
] | 585 |
train
|
NCT00054925
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Loss Maintenance (WLM)
Brief Summary: To determine the effectiveness of continuous patient contact on weight loss maintenance.
|
{
"A": "Arm Label: CHF patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: COPD patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: CHF patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPD patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IVR-Enhanced Care; Assigned to Arm(s): CHF patients, IVR-Enhanced Care, COPD patients, IVR-Enhanced Care",
"B": "Arm Label: Personal contact (PC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Personal contact (PC) | Arm Label: Interactive technology (IT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive technology (IT) | Intervention Type: BEHAVIORAL; Name: Personal contact (PC); Assigned to Arm(s): Personal contact (PC) | Intervention Type: BEHAVIORAL; Name: Interactive technology (IT); Assigned to Arm(s): Interactive technology (IT)",
"C": "Arm Label: Safety Training; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Safety Training | Arm Label: Personal Health Partner and Counseling (PHP+C); Type: EXPERIMENTAL; Interventions: Behavioral: Personal Health Partner and Counseling (PHP+C) | Intervention Type: BEHAVIORAL; Name: Safety Training; Assigned to Arm(s): Safety Training | Intervention Type: BEHAVIORAL; Name: Personal Health Partner and Counseling (PHP+C); Assigned to Arm(s): Personal Health Partner and Counseling (PHP+C)",
"D": "Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Drug: Stepped care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Stepped care; Assigned to Arm(s): Stepped Care"
}
|
B
|
[
"NCT01135381",
"NCT00054925",
"NCT01188629",
"NCT00926588"
] | 586 |
train
|
NCT00055120
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy
Brief Summary: The purpose of this study is to evaluate the effect of starting anti-HIV drugs in HIV infected patients who are being treated for opportunistic infections (OIs). This study will follow two patient groups: those who received anti-HIV drugs soon after being diagnosed with an OI and patients with OIs who deferred beginning anti-HIV drugs until after recovering from the OI.
|
{
"A": "Arm Label: Early antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Other: Early antiretroviral therapy | Arm Label: Standard antiretroviral therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early antiretroviral therapy; Assigned to Arm(s): Early antiretroviral therapy",
"B": "Intervention Type: DRUG; Name: Emtricitabine/tenofovir disoproxil fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A",
"C": "Arm Label: Earlier HIV Therapy; Type: EXPERIMENTAL; Interventions: Drug: efavirenz, Biological: nucleoside | Arm Label: Deferred HIV Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: efavirenz, Biological: nucleoside | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy | Intervention Type: BIOLOGICAL; Name: nucleoside; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2"
}
|
B
|
[
"NCT00976040",
"NCT00055120",
"NCT01075152",
"NCT00830856"
] | 587 |
train
|
NCT00055120
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy
Brief Summary: The purpose of this study is to evaluate the effect of starting anti-HIV drugs in HIV infected patients who are being treated for opportunistic infections (OIs). This study will follow two patient groups: those who received anti-HIV drugs soon after being diagnosed with an OI and patients with OIs who deferred beginning anti-HIV drugs until after recovering from the OI.
|
{
"A": "Arm Label: Combination intervention + incentives; Type: EXPERIMENTAL; Interventions: Other: Point of care CD4+ after HIV diagnosis, Other: Accelerated ART initiation, Behavioral: SMS appointment reminders, Other: Non-cash Financial Incentives | Arm Label: Combination intervention strategy(CIS); Type: EXPERIMENTAL; Interventions: Other: Point of care CD4+ after HIV diagnosis, Other: Accelerated ART initiation, Behavioral: SMS appointment reminders | Arm Label: Standard of care (SOC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Point of care CD4+ after HIV diagnosis; Assigned to Arm(s): Combination intervention + incentives, Combination intervention strategy(CIS) | Intervention Type: OTHER; Name: Accelerated ART initiation; Assigned to Arm(s): Combination intervention + incentives, Combination intervention strategy(CIS) | Intervention Type: BEHAVIORAL; Name: SMS appointment reminders; Assigned to Arm(s): Combination intervention + incentives, Combination intervention strategy(CIS) | Intervention Type: OTHER; Name: Non-cash Financial Incentives; Assigned to Arm(s): Combination intervention + incentives",
"B": "Arm Label: Early antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Other: Early antiretroviral therapy | Arm Label: Standard antiretroviral therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early antiretroviral therapy; Assigned to Arm(s): Early antiretroviral therapy",
"C": "Intervention Type: DRUG; Name: Emtricitabine/tenofovir disoproxil fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A",
"D": "Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiretroviral medications | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: Antiretroviral medications+Isoniazid prophylaxis | Arm Label: III; Type: EXPERIMENTAL; Interventions: Drug: Antiretroviral medications | Arm Label: IV; Type: EXPERIMENTAL; Interventions: Drug: Antiretroviral medications+Isoniazid prophylaxis | Intervention Type: DRUG; Name: Antiretroviral medications; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Antiretroviral medications+Isoniazid prophylaxis; Assigned to Arm(s): II | Intervention Type: DRUG; Name: Antiretroviral medications; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Antiretroviral medications+Isoniazid prophylaxis; Assigned to Arm(s): IV"
}
|
C
|
[
"NCT01930084",
"NCT00976040",
"NCT00055120",
"NCT00495651"
] | 588 |
train
|
NCT00055315
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cognitive Group Treatment for Borderline Outpatients
Brief Summary: This study will expose patients to either a Systems Training for Emotional Predictability and Problem Solving (STEPPS) or treatment as usual (TAU) to determine the more effective therapy for treating borderline personality disorder.
|
{
"A": "Arm Label: STEPPS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Systems Training for Emotional Predictability and Problem Solving (STEPPS) | Arm Label: Treatment as Usual; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: Systems Training for Emotional Predictability and Problem Solving (STEPPS); Assigned to Arm(s): STEPPS | Intervention Type: BEHAVIORAL; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment as Usual",
"B": "Arm Label: Cognitive Analytic Informed Brief Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive analytic informed brief therapy | Arm Label: Treatment As Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive analytic informed brief therapy; Assigned to Arm(s): Cognitive Analytic Informed Brief Therapy",
"C": "Arm Label: CHESS Mobile Health Group; Type: EXPERIMENTAL; Interventions: Device: CHESS Mobile Health smart phone application, Behavioral: Problem solving therapy | Intervention Type: DEVICE; Name: CHESS Mobile Health smart phone application; Assigned to Arm(s): CHESS Mobile Health Group | Intervention Type: BEHAVIORAL; Name: Problem solving therapy; Assigned to Arm(s): CHESS Mobile Health Group",
"D": "Arm Label: Non-Education; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Non-Education | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education | Intervention Type: BEHAVIORAL; Name: Non-Education; Assigned to Arm(s): Non-Education"
}
|
A
|
[
"NCT00055315",
"NCT03853382",
"NCT02718248",
"NCT01719731"
] | 589 |
train
|
NCT00055315
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cognitive Group Treatment for Borderline Outpatients
Brief Summary: This study will expose patients to either a Systems Training for Emotional Predictability and Problem Solving (STEPPS) or treatment as usual (TAU) to determine the more effective therapy for treating borderline personality disorder.
|
{
"A": "Arm Label: STEPPS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Systems Training for Emotional Predictability and Problem Solving (STEPPS) | Arm Label: Treatment as Usual; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: Systems Training for Emotional Predictability and Problem Solving (STEPPS); Assigned to Arm(s): STEPPS | Intervention Type: BEHAVIORAL; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment as Usual",
"B": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group 1, Group 2",
"C": "Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2"
}
|
A
|
[
"NCT00055315",
"NCT03498937",
"NCT02387736",
"NCT00603421"
] | 590 |
train
|
NCT00055315
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cognitive Group Treatment for Borderline Outpatients
Brief Summary: This study will expose patients to either a Systems Training for Emotional Predictability and Problem Solving (STEPPS) or treatment as usual (TAU) to determine the more effective therapy for treating borderline personality disorder.
|
{
"A": "Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care",
"B": "Arm Label: STEPPS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Systems Training for Emotional Predictability and Problem Solving (STEPPS) | Arm Label: Treatment as Usual; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: Systems Training for Emotional Predictability and Problem Solving (STEPPS); Assigned to Arm(s): STEPPS | Intervention Type: BEHAVIORAL; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment as Usual",
"C": "Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS",
"D": "Arm Label: Mindfulness training; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness training; Assigned to Arm(s): Mindfulness training"
}
|
B
|
[
"NCT00736918",
"NCT00055315",
"NCT01512602",
"NCT00892138"
] | 591 |
train
|
NCT00055315
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cognitive Group Treatment for Borderline Outpatients
Brief Summary: This study will expose patients to either a Systems Training for Emotional Predictability and Problem Solving (STEPPS) or treatment as usual (TAU) to determine the more effective therapy for treating borderline personality disorder.
|
{
"A": "Arm Label: STEPPS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Systems Training for Emotional Predictability and Problem Solving (STEPPS) | Arm Label: Treatment as Usual; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: Systems Training for Emotional Predictability and Problem Solving (STEPPS); Assigned to Arm(s): STEPPS | Intervention Type: BEHAVIORAL; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment as Usual",
"B": "Arm Label: BI 1358894 5mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: BI 1358894 25mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: BI 1358894 75mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: BI 1358894 125mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1358894; Assigned to Arm(s): BI 1358894 125mg, BI 1358894 25mg, BI 1358894 5mg, BI 1358894 75mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo",
"D": "Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00055315",
"NCT04566601",
"NCT00533117",
"NCT00131781"
] | 592 |
train
|
NCT00056056
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides
Brief Summary: RATIONALE: Ultraviolet light therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. It is not yet known whether ultraviolet light therapy is more effective with or without bexarotene in treating mycosis fungoides.
PURPOSE: Randomized phase III trial to compare the effectiveness of ultraviolet light therapy using methoxsalen with or without bexarotene in treating patients who have mycosis fungoides.
|
{
"A": "Arm Label: Bexarotene and PUVA; Type: EXPERIMENTAL; Interventions: Drug: bexarotene, Drug: methoxypsoralen, Procedure: UV light therapy | Arm Label: PUVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: methoxypsoralen, Procedure: UV light therapy | Intervention Type: DRUG; Name: bexarotene; Assigned to Arm(s): Bexarotene and PUVA | Intervention Type: DRUG; Name: methoxypsoralen; Assigned to Arm(s): Bexarotene and PUVA, PUVA | Intervention Type: PROCEDURE; Name: UV light therapy; Assigned to Arm(s): Bexarotene and PUVA, PUVA",
"B": "Arm Label: lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): lenalidomide",
"C": "Arm Label: 1 (PG - NM (MCH) 0.02%); Type: ACTIVE_COMPARATOR; Interventions: Drug: mechlorethamine-MCH (nitrogen mustard) | Arm Label: 2 (AP - MCH(NM) 0.02%); Type: ACTIVE_COMPARATOR; Interventions: Drug: mechlorethamine-MCH (nitrogen mustard) | Intervention Type: DRUG; Name: mechlorethamine-MCH (nitrogen mustard); Assigned to Arm(s): 1 (PG - NM (MCH) 0.02%), 2 (AP - MCH(NM) 0.02%)",
"D": "Arm Label: Brentuximab vedotin; Type: EXPERIMENTAL; Interventions: Drug: Brentuximab Vedotin | Arm Label: Methotrexate or Bexarotene; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Bexarotene | Intervention Type: DRUG; Name: Brentuximab Vedotin; Assigned to Arm(s): Brentuximab vedotin | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate or Bexarotene | Intervention Type: DRUG; Name: Bexarotene; Assigned to Arm(s): Methotrexate or Bexarotene"
}
|
A
|
[
"NCT00056056",
"NCT01098656",
"NCT00168064",
"NCT01578499"
] | 593 |
train
|
NCT00056212
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Yoga for Chronic Low Back Pain
Brief Summary: This study will compare the effectiveness of yoga classes, exercise classes, and a self-care book in the management of pain and function for people with low back pain.
|
{
"A": "Arm Label: Individual Cognitive Functional Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Cognitive Functional Therapy | Arm Label: Group Exercise Classes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Exercise Classes | Intervention Type: BEHAVIORAL; Name: Individual Cognitive Functional Therapy; Assigned to Arm(s): Individual Cognitive Functional Therapy | Intervention Type: BEHAVIORAL; Name: Group Exercise Classes; Assigned to Arm(s): Group Exercise Classes",
"B": "Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): N/A",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Chiropractic Manual treatment + home exercise (procedure+behavior) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Supervised rehabilitative exercise+home exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home exercise | Intervention Type: PROCEDURE; Name: Chiropractic Manual treatment + home exercise (procedure+behavior); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Supervised rehabilitative exercise+home exercise; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Home exercise; Assigned to Arm(s): 3",
"D": "Intervention Type: BEHAVIORAL; Name: Fear-reducing Information; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Symptom-based exercise; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT02145728",
"NCT00056212",
"NCT00269321",
"NCT00410319"
] | 594 |
train
|
NCT00056212
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Yoga for Chronic Low Back Pain
Brief Summary: This study will compare the effectiveness of yoga classes, exercise classes, and a self-care book in the management of pain and function for people with low back pain.
|
{
"A": "Arm Label: Yoga; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weekly yoga classes | Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual physical therapy treatment | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Weekly yoga classes; Assigned to Arm(s): Yoga | Intervention Type: BEHAVIORAL; Name: Individual physical therapy treatment; Assigned to Arm(s): Physical Therapy | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education",
"B": "Arm Label: Yoga Class Twice Per Week; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga class twice per week | Arm Label: Yoga Class Once per Week; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga class once per week | Intervention Type: BEHAVIORAL; Name: Yoga class once per week; Assigned to Arm(s): Yoga Class Once per Week | Intervention Type: BEHAVIORAL; Name: Yoga class twice per week; Assigned to Arm(s): Yoga Class Twice Per Week",
"C": "Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care book recommendations | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Self-care book recommendations; Assigned to Arm(s): 3"
}
|
C
|
[
"NCT01343927",
"NCT01761617",
"NCT00056212",
"NCT00447668"
] | 595 |
train
|
NCT00056212
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Yoga for Chronic Low Back Pain
Brief Summary: This study will compare the effectiveness of yoga classes, exercise classes, and a self-care book in the management of pain and function for people with low back pain.
|
{
"A": "Arm Label: Yoga Class Twice Per Week; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga class twice per week | Arm Label: Yoga Class Once per Week; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga class once per week | Intervention Type: BEHAVIORAL; Name: Yoga class once per week; Assigned to Arm(s): Yoga Class Once per Week | Intervention Type: BEHAVIORAL; Name: Yoga class twice per week; Assigned to Arm(s): Yoga Class Twice Per Week",
"B": "Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): N/A",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care book recommendations | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Self-care book recommendations; Assigned to Arm(s): 3",
"D": "Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Arm Label: Yoga; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): Yoga"
}
|
B
|
[
"NCT01761617",
"NCT00056212",
"NCT00447668",
"NCT02224183"
] | 596 |
train
|
NCT00056277
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind Placebo Controlled Study of Lamictal in Acute Bipolar Depression
Brief Summary: A Placebo Controlled Study Evaluating Efficacy and Safety of Medication in Patients with Bipolar Disorder
|
{
"A": "Arm Label: Arm 1; Type: OTHER; Interventions: Drug: lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): Arm 1",
"B": "Intervention Type: BEHAVIORAL; Name: Psychoeduction; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): N/A",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BW430C(lamotrigine); Type: ACTIVE_COMPARATOR; Interventions: Drug: lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): BW430C(lamotrigine) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: lamotrigine | Arm Label: lamotrigine; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00056277",
"NCT00188838",
"NCT00550407",
"NCT00274677"
] | 597 |
train
|
NCT00056316
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Depression in Dementia Caregivers
Brief Summary: The purpose of this study was to develop and examine the initial impact of a distance-based intervention for female family dementia caregivers. As stated in the original proposal, the primary hypothesis of the study was that family caregivers who participated in the Video Intervention would show greater reduction in psychological distress (i.e., on measures of depression and emotional distress following problematic patient behaviors) compared to those in the Basic Education condition, and that this effect would be maintained over time (3 and 6 months post-tx).
|
{
"A": "Arm Label: Behavioral Skills Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Skills Training: Experimental | Arm Label: Basic Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Education | Intervention Type: BEHAVIORAL; Name: Basic Education; Assigned to Arm(s): Basic Education | Intervention Type: BEHAVIORAL; Name: Behavioral Skills Training: Experimental; Assigned to Arm(s): Behavioral Skills Training",
"B": "Arm Label: Immediately Receive Tool; Type: EXPERIMENTAL; Interventions: Behavioral: Immediately Receive Tool | Arm Label: One Month Delay; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: One Month Delay | Intervention Type: BEHAVIORAL; Name: Immediately Receive Tool; Assigned to Arm(s): Immediately Receive Tool | Intervention Type: BEHAVIORAL; Name: One Month Delay; Assigned to Arm(s): One Month Delay",
"C": "Arm Label: Care Notebook; Type: OTHER; Interventions: Behavioral: Care Notebook | Arm Label: Care Notebook + Parent Navigator; Type: EXPERIMENTAL; Interventions: Behavioral: Parent Navigator, Behavioral: Care Notebook | Intervention Type: BEHAVIORAL; Name: Parent Navigator; Assigned to Arm(s): Care Notebook + Parent Navigator | Intervention Type: BEHAVIORAL; Name: Care Notebook; Assigned to Arm(s): Care Notebook, Care Notebook + Parent Navigator",
"D": "Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: light support, Other: 3 preventive home visits by a nurse | Arm Label: UP Protocol; Type: EXPERIMENTAL; Interventions: Other: Case Manager, Other: 3 preventive home visits by a nurse | Arm Label: UP-TECH Protocol; Type: EXPERIMENTAL; Interventions: Other: Case Manager, Other: Assistive Technologies, Other: 3 preventive home visits by a nurse | Intervention Type: OTHER; Name: Case Manager; Assigned to Arm(s): UP Protocol, UP-TECH Protocol | Intervention Type: OTHER; Name: Assistive Technologies; Assigned to Arm(s): UP-TECH Protocol | Intervention Type: OTHER; Name: light support; Assigned to Arm(s): Usual Care | Intervention Type: OTHER; Name: 3 preventive home visits by a nurse; Assigned to Arm(s): UP Protocol, UP-TECH Protocol, Usual Care"
}
|
A
|
[
"NCT00056316",
"NCT02420535",
"NCT02643472",
"NCT01700556"
] | 598 |
train
|
NCT00056407
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Brief Summary: This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.
|
{
"A": "Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle",
"B": "Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm",
"C": "Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: combined sono-electro-magnetic therapy (Sonodyn Medico Star) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo therapy (Placebo Sonodyn Medico Star) | Intervention Type: DEVICE; Name: combined sono-electro-magnetic therapy (Sonodyn Medico Star); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: placebo therapy (Placebo Sonodyn Medico Star); Assigned to Arm(s): 2"
}
|
B
|
[
"NCT02588274",
"NCT00056407",
"NCT00434343",
"NCT00688506"
] | 599 |
train
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.